Curriculum VitaeLast Updated: 03/02/2020

PERSONAL DATAName: Robin K. Ohls, M.D.Citizenship: United States

EDUCATIONYears Degree Institution (Area of Study)

1990 - 1993 Fellow University of Utah School of Medicine(Neonatology)Salt Lake City, UT

1987 - 1990 Resident University of Utah School of Medicine (Pediatrics)Salt Lake City, UT

1984 - 1987 M.D. University of Utah School of Medicine (Medicine)Salt Lake City, UT

1983 - 1984 University of Southern California School ofMedicine (Medicine)Los Angeles, CA

1979 - 1983 B.A. Stanford University (Human Biology)Stanford, CA

BOARD CERTIFICATIONS11/14/1990 -12/31/2007

American Board of Pediatrics (Pediatrics), Expired

09/01/1993 - Present American Board of Pediatrics (Sub: Neonatal-Perinatal Medicine), Certified

CURRENT LICENSES/CERTIFICATIONS1996 - Present Neonatal Resuscitation Program Instructor2018 - 2022 State License (UT) - Physician (MD)2018 - 2021 Controlled Substance (UT) - Physician (MD)

UNIVERSITY OF UTAH ACADEMIC HISTORYPediatrics (General Pediatrics), 07/01/1992 - 07/01/199307/01/1992 - 07/01/1993 Instructor

Pediatrics (Neonatology), 01/01/2019 - Present01/01/2019 Professor

PROFESSIONAL EXPERIENCEFull-Time Positions2019 - Present Professor, Department of Pediatrics, University of Utah, Salt Lake City, UT2005 - 2018 Professor with Tenure, Department of Pediatrics, University of New Mexico

School of Medicine, Albuquerque, NM

Ohls, Page 1

1999 - 2005 Associate Professor with Tenure, Department of Pediatrics, University of NewMexico School of Medicine, Albuquerque, NM

1995 - 1999 Assistant Professor, Department of Pediatrics, University of New Mexico Schoolof Medicine, Albuquerque, NM

1993 - 1995 Assistant Professor, Department of Pediatrics, University of Florida College ofMedicine, Gainesville, FL

Editorial Experience2019 - 2020 Editor for special Erythropoietin edition of International Journal of Molecular

Science, 20202014 - Present Editorial Board for Maternal Health, Neonatology and Perinatology2007 - 2018 Ohls RK, Yoder M (Eds): Questions and Controversies in Neonatology Series:

Hematology, Immunology, and Infectious Diseases. Philadelphia, Elsevier HealthScience, 2007. Ohls RK, Maheshwari A (Eds): Questions and Controversies inNeonatology Series: Hematology, Immunology, and Infectious Diseases, SecondEdition. Philadelphia, Elsevier Health Science, 2012. Ohls RK, Maheshwari A,Christensen RD (Eds): Questions and Controversies in Neonatology Series:Hematology, Immunology, and Genetics, Third Edition. Philadelphia, ElsevierHealth Science, 2018.

2002 Guest Editor for Transfusion Alternatives to Transfusion Medicine, PediatricsEdition, Volume 4, Number 1

Reviewer ExperienceReviewer for Pediatrics, Journal of Pediatrics, Journal of Perinatology, PediatricResearch, Transfusion, Neonatology, JAMA, PLOS, American Journal ofPerinatology, Journal of Maternal, Fetal and Neonatal Medicine

SCHOLASTIC HONORS2014 Excellence in Clinical Research Award, University of New Mexico Health

Sciences Center, Albuquerque, NM2013 Rue Wright Clinical Research Award Finalist, International Congress of Pediatrics,

Melbourne, Australia2007 Scholar’s Award Winner, Western Society for Pediatric Research, Carmel, CA2006 Housestaff Award Winner, Society for Pediatric Research, Neonatology Session,

San Francisco, CA2004 Champion of Advocacy Award, American Society of Hematology2004 Glenn Peak Clinical Research Award, General Clinical Research Center,

University of New Mexico School of Medicine, Albuquerque, NM2003 Student Award Winner, Western Society for Pediatric Research, Carmel, CA2001 Article selected for review in The Yearbook of Neonatal and Perinatal Medicine1999 - 2000 Faculty Teaching Award, University of New Mexico School of Medicine,

Albuquerque, NM1999 Article selected for review in The Yearbook of Pediatrics1998 Young Investigator, Perinatal Research Society Annual Meeting, Park City, UT1997 Phase 2 Tutor Teaching Award, University of New Mexico School of Medicine,

Albuquerque, NM

Ohls, Page 2

1996 - 1997 Faculty Teaching Award, Department of Pediatrics, University of New MexicoSchool of Medicine, Albuquerque, NM

1996 Article selected for review in The Yearbook of Neonatal and Perinatal Medicine1996 Article selected for review in The Yearbook of Pediatrics1995 Article selected for review in The Yearbook of Neonatal and Perinatal Medicine1994 - 1995 Faculty Teaching Award, Department of Pediatrics, University of Florida School

of Medicine, Gainesville, FL1992 Fellow's Travel Award, Developmental Biology, Western Society for Clinical

Investigation, Carmel, CA1991 Fellow's Travel Award, Perinatology, Western Society for Pediatric Research,

Carmel, CA1989 - 1990 Pediatric Teaching Award, University of Utah School of Medicine, Salt Lake City,

UT1986 - 1987 Honors Program, Department of Pediatrics, University of Utah School of

Medicine, Salt Lake City, UT1984 Pediatric Research Fellowship, University of Utah School of Medicine, Salt Lake

City, UT

ADMINISTRATIVE EXPERIENCEProfessional Organization & Scientific Activities2019 Grant Reviewer, National Institute of Neurological Disorders and Stroke,

Reviewed P-01 applications for NIH NINDS2017 - Present Member, National Institute of Arthritis and Musculoskeletal Skin Diseases, Data

Safety Monitoring Board, TNF-alpha blockade with Certolizumab to preventpregnancy complications in high-risk patients with APS

2016 - Present Member, National Institute of Neurological Disorders and Stroke, Data SafetyMonitoring Board, High Dose Erythropoietin for Asphyxia and Encephalopathy(HEAL)

2013 - 2014 President, Western Society for Pediatric Research2010 - 2012 National Board Member, Clinical & Translational Science Awards Consortium,

Child Health Oversight Committee2009 - 2013 Chair, American Academy of Pediatrics - District VIII, Scientific Review

Committee2008 - 2012 Member, National Institute of Child Health and Human Development, Data Safety

Monitoring Board, High-dose Epo for Neonates Requiring Heart Surgery2007 - 2011 Secretary/Treasurer, Western Society for Pediatric Research2005 - 2013 Member, American Academy of Pediatrics - District VIII, Scientific Review

Committee2005 - 2007 Medical Director, National Institutes of Health, General Clinical Research Center,

Research Subject Advocate Office2004 Co-Moderator, Society for Pediatric Research, Pediatric Academic Societies

Annual Meeting, Neonatal-Perinatal Clinical Trials Session, San Francisco, CA2004 Co-Moderator, Western Society for Pediatric Research, Developmental Biology

Session, Carmel, CA2004 - 2007 Council Member, Western Society for Pediatric Research

Ohls, Page 3

2004 - 2005 Member, Society for the Advancement of Blood Management, ConferencePlanning Committee

2002 Co-Moderator, Society for Pediatric Research, Pediatric Academic SocietiesAnnual Meeting, Neonatal-Perinatal Clinical Trials Session, Baltimore, MD

2002 Co-Moderator, Western Society for Pediatric Research, Developmental BiologySession, Carmel, CA

2001 Co-Moderator, Society for Pediatric Research, Pediatric Academic SocietiesAnnual Meeting, Neonatal-Perinatal Clinical Trials Session, Baltimore, MD

2000 Co-Moderator, Western Society for Pediatric Research, General NeonatologySession, Carmel, CA

1998 - 2007 Member, National Institutes of Health, General Clinical Research Center, AdvisoryCouncil

1997 - 2019 Moderator, Society for Pediatric Research, Pediatric Academic Societies AnnualMeeting, Neonatal-Perinatal Clinical Trials Sessions; Neonatal Hematology;Neonatal Outcomes

Grant Review Committee/Study Section2010 - Present Grant Reviewer, Canadian Institutes of Health Research2007 Study Section Member, K07 Grant, National Institutes of Health2004 - Present Study Section Member, Program Project Grant, National Institutes of Health2004 - Present Grant Reviewer, U.S. Civilian Research & Development Foundation2004 - Present Grant Reviewer, Thrasher Research Fund2004 Grant Reviewer, Swiss National Science Foundation2003 Grant Reviewer, Canadian Institutes of Health Research

Symposium/Meeting Chair/Coordinator2020 - 2021 Organizing Chair, 42nd Western Conference on Perinatal Research, sponsored

by the American Academy of Pediatrics Section on Neonatal-Perinatal Medicine.The Western Conference on Perinatal Research draws from centers in the states ofWashington, Oregon, California, Utah, Hawaii, Texas, Oklahoma, New Mexico,Arizona and Colorado with the goal of promoting an interchange of the newestscientific and clinical discoveries in neonatology and perinatal medicine.

2019 - 2020 Organizing Committee Member, 41stWestern Conference on PerinatalResearch (see above)

PROFESSIONAL COMMUNITY ACTIVITIES2016 Interviewee, Albuquerque Journal, Blood-boosters may give preemies an edge2009 - Present Member, Thrasher Research Fund, Data Safety Monitoring Board,

NEAT/NEAT-O Study2002 Moderator, Foundation Acta Paediatrica, International Conference on Neonatal

Hematology and Immunology, Session on Erythropoietin, Orlando, FL1993 - Present Clinical Advisor & Consultant, Private Consulting, NICUs. Consultant for

Neonatal Care Providers Nationally and Internationally on the use of erythropoiesisstimulating agents in preterm and term infants

Ohls, Page 4

UNIVERSITY COMMUNITY ACTIVITIESUniversity of Utah Health2020 - Present Active Member, Institutional Review Board

College Level2019 - Present Active Member, School of Medicine Faculty Appointment Review and

Advancement Committee

SERVICE AT PREVIOUS INSTITUTIONS2016 - Present Division Chief, University of New Mexico School of Medicine, Neonatology2013 - Present Director, University of New Mexico School of Medicine, Department of Pediatrics,

Neonatal Research2007 - 2012 Director, University of New Mexico School of Medicine, Clinical & Translational

Science Center, Pediatric Integration2007 - 2008 Chair, University of New Mexico School of Medicine, Clinical & Translational

Science Center, Scholar Selection, Search Committee2006 - 2009 Member, University of New Mexico School of Medicine, Health Sciences Center,

Promotion, Review and Tenure Committee2003 - 2009 Member, University of New Mexico Health Sciences Center, Human Research

Review Committee2000 - 2011 Member, University of New Mexico School of Medicine, Department of

Pediatrics, Residency Education Committee1998 - Present Member, University of New Mexico School of Medicine, Department of

Pediatrics, Research Review Committee1998 - Present Member, University of New Mexico School of Medicine, Department of

Pediatrics, Promotion, Review and Tenure Committee1998 - 2009 Member, University of New Mexico School of Medicine, Department of

Pediatrics, Residency Training Committee1996 - 2008 Member, University of New Mexico School of Medicine, Department of

Pediatrics, Phase II Curriculum Committee1996 - 2005 Member, University of New Mexico School of Medicine, Department of

Pediatrics, Intern Selection Committee1996 - 1999 Medical Director, University of New Mexico School of Medicine, Department of

Pediatrics, Newborn Transport/Neonatal Nurse Practitioners1995 - 1998 Member, University of New Mexico School of Medicine, Dean’s Science Advisory

Council

CURRENT MEMBERSHIPS IN PROFESSIONAL SOCIETIESAmerican Academy of PediatricsAmerican Academy of Pediatrics - District VIII Section on Perinatal PediatricsAmerican Pediatric SocietyPerinatal Research SocietySociety for Pediatric ResearchWestern Society for Pediatric Research

Ohls, Page 5

FUNDINGActive Grants06/01/17 - 05/31/22 Darbepoetin Trial to Improve Red Cell Mass and Neurodevelopment in Preterm

Infants(IND 100138; Clinical Trials # NCT03169881)Principal Investigator(s): Robin K. OhlsNational Institutes of HealthRole: Principal Investigator

04/01/16 - 03/31/21 Neonatal Research Network (U10 HD27881)  (Due to Covid-19, the PI transferfrom Dr. Yoder to Dr. Ohls is anticipated to occur in July 2020) Principal Investigator(s): Robin K. OhlsNational Institutes of HealthRole: Principal Investigator

Past Grants12/01/14 - 11/30/15 Assessment of Worldwide Acute Kidney injury Epidemiology in Neonates

Principal Investigator(s): Robin K. Ohls; WongNational Institutes of HealthRole: Co-Principal Investigator

01/01/14 - 12/31/19 CoBRE Center for Brain Recovery and RepairPrincipal Investigator(s): Robin K. Ohls; ShuttleworthNational Institutes of HealthRole: Co-Principal Investigator

04/01/13 - 03/31/18 Preterm Epo Neuroprotection Trial (PENUT)(Clinical Trials #NCT01534481; IND#12656)Principal Investigator(s): Robin K. Ohls; JuulNational Institutes of HealthRole: Co-Principal Investigator

12/01/12 - 11/30/13 Biomarker profiles of preterm infants who develop necrotizing enterocolitisPrincipal Investigator(s): Robin K. Ohls; ManiNational Institutes of HealthRole: Co-Principal Investigator

12/01/12 - 11/30/13 Determination of fetal RhD status using fetal nucleic acid isolated from thematernal circulationPrincipal Investigator(s): Robin K. OhlsNational Institutes of HealthRole: Principal Investigator

11/01/12 - 12/31/15 Development of human fetal pancreatic assay to evaluate effects of HIP2B ongrowth and differentiationPrincipal Investigator(s): Robin K. OhlsCureDM, Inc.Role: Principal Investigator

Ohls, Page 6

10/01/12 - 09/30/14 Darbepoetin Administration to Infants undergoing cooling for encephalopathy: TheDANCE Study(Clinical Trials #NCT 01471015; IND#113284)Principal Investigator(s): Robin K. Ohls; BasergaThrasher Research FundRole: Co-Principal Investigator

10/01/11 - 06/30/12 Signature Program in Child HealthMethylation in Regions of Executive Function in Developing Human BrainPrincipal Investigator(s): Robin K. OhlsUniversity of New Mexico School of MedicineRole: Principal Investigator

07/01/10 - 01/31/12 Clinical & Translational Science CenterNational Institutes of HealthRole: Director of Pediatric Integration

03/01/10 - 02/28/16 Brain imaging and developmental follow-up of infants treated with erythropoietin:The BRITE Study(Clinical Trials #NCT01207778)Principal Investigator(s): Robin K. OhlsNational Institutes of HealthRole: Principal Investigator

01/01/10 - 12/31/16 NIH M01 RR 00997/NCRR #1 UL1 TR000154-01Brain Imaging and Developmental follow up of Infants Treated withErythropoietin(HRRC # 10-153)Principal Investigator(s): Robin K. OhlsUniversity of New Mexico Clinical & Translational Science CenterRole: Principal Investigator

07/01/09 - 11/30/12 Department of Pediatrics Research GrantInflammatory mediators as predictors of neonatal sepsis and recoveryPrincipal Investigator(s): Robin K. OhlsUniversity of New Mexico School of MedicineRole: Principal Investigator

01/01/09 - 06/30/11 Epo Neuroprotection of ELBW Infants: Planning GrantNational Institutes of HealthRole: Co-Investigator

01/01/08 - 12/31/12 NIH M01 RR 00997/NCRR #1 UL1 TR000154-01Randomized Clinical Trial of Inhaled PGE1 in Neonatal Hypoxemic RespiratoryFailure(HRRC # 08-100)Principal Investigator(s): Robin K. OhlsUniversity of New Mexico Clinical & Translational Science CenterRole: Principal Investigator

Ohls, Page 7

01/01/08 - 12/31/12 NIH M01 RR 00997/NCRR #1 UL1 TR000154-01Determination of fetal RhD status using fetal nucleic acids in the maternalcirculation(HRRC # 08-619)Principal Investigator(s): Robin K. OhlsUniversity of New Mexico Clinical & Translational Science CenterRole: Principal Investigator

01/01/08 - 12/31/12 NIH M01 RR 00997/NCRR #1 UL1 TR000154-01Brain Imaging and Developmental follow up of Infants Treated withErythropoietin Pilot Study(HRRC # 08-085)Principal Investigator(s): Robin K. OhlsUniversity of New Mexico Clinical & Translational Science CenterRole: Co-Principal Investigator

07/01/07 - 11/30/12 Biomarker Profiles for Early Diagnosis of Sepsis in NeonatesPrincipal Investigator(s): Robin K. OhlsNational Institutes of HealthRole: Co-Principal Investigator

01/01/07 - 12/31/11 NIH M01 RR 00997/NCRR #1 UL1 TR000154-01Biomarker profiles in neonatal sepsis and recovery(HRRC # 07-150)Principal Investigator(s): Robin K. OhlsUniversity of New Mexico Clinical & Translational Science CenterRole: Principal Investigator

07/01/06 - 06/30/08 Department of Pediatrics Research GrantErythropoietin gene and protein expression in the developing human eyePrincipal Investigator(s): Robin K. OhlsUniversity of New Mexico School of MedicineRole: Principal Investigator

06/01/06 - 10/31/13 A randomized, masked, placebo controlled study to assess the safety and efficacyof darbepoetin alfa administered to preterm infants(Clinical Trials #NCT00334737; IND#100138)Principal Investigator(s): Robin K. OhlsThrasher Research FundRole: Principal Investigator

01/01/06 - 12/31/10 NIH M01 RR 00997/NCRR #1 UL1 TR000154-01A randomized, masked, placebo controlled study to assess the safety and efficacyof darbepoetin alfa administered to preterm infants(HRRC 06-139)Principal Investigator(s): Robin K. OhlsUniversity of New Mexico Clinical & Translational Science CenterRole: Principal Investigator

09/01/05 - 08/31/06 Methylation of Epo gene during fetal developmentPrincipal Investigator(s): Robin K. OhlsUniversity of New Mexico Health Sciences Center Research Allocation CommitteeRole: Principal Investigator

Ohls, Page 8

01/01/05 - 12/31/09 NIH M01 RR 00997/NCRR #1 UL1 TR000154-01A randomized, masked study of weekly erythropoietin dosing in neonates(HRRC 05-380)Principal Investigator(s): Robin K. OhlsUniversity of New Mexico Clinical & Translational Science CenterRole: Principal Investigator

01/01/04 - 12/31/06 NIH M01 RR 00997/NCRR #1 UL1 TR000154-01The ability of healthcare providers to predict anticipatory grief in the NICU(HRRC 03-374)Principal Investigator(s): Robin K. OhlsUniversity of New Mexico Clinical & Translational Science CenterRole: Co-Principal Investigator

01/01/04 - 12/31/06 NIH M01 RR 00997/NCRR #1 UL1 TR000154-01A randomized, dose-response study to assess the safety and preliminary efficacy ofDarbepoetin alfa administration to preterm infants(HRRC 04-046)Principal Investigator(s): Robin K. OhlsUniversity of New Mexico Clinical & Translational Science CenterRole: Principal Investigator

08/01/03 - 06/30/05 Biosignature Study GrantInflammatory mediators as predictors of neonatal sepsis and recoveryPrincipal Investigator(s): Robin K. OhlsRules-Based Medicine, Inc.Role: Principal Investigator

01/01/03 - 12/31/06 NIH M01 RR 00997/NCRR #1 UL1 TR000154-01Inflammatory mediators as predictors of neonatal sepsis and recovery(HRRC 03-053)Principal Investigator(s): Robin K. OhlsUniversity of New Mexico Clinical & Translational Science CenterRole: Co-Principal Investigator

08/01/02 - 08/31/04 Clinical Investigator GrantA multicenter phase I/II study to determine antibody concentrations and assess thesafety of administration of INH-A21, a donor- selected human staphylococcalimmune globulin in low birthweight infantsPrincipal Investigator(s): Robin K. OhlsInhibitex IncRole: Principal Investigator

08/01/02 - 07/31/03 Pharmaceutical GrantEvaluation of Novel Erythropoiesis Stimulating Protein (NESP) on the growth offetal and neonatal erythroid progenitorsPrincipal Investigator(s): Robin K. OhlsAmgen Inc.Role: Principal Investigator

Ohls, Page 9

01/01/02 - 12/31/05 NIH M01 RR 00997/NCRR #1 UL1 TR000154-01Evaluation of Novel Erythropoiesis Stimulating Protein (NESP) on the growth offetal and neonatal erythroid progenitors(HRRC 02-388)Principal Investigator(s): Robin K. OhlsUniversity of New Mexico Clinical & Translational Science CenterRole: Principal Investigator

01/01/02 - 12/31/04 NIH M01 RR 00997/NCRR #1 UL1 TR000154-01A multicenter phase II study to assess the safety and preliminary efficacy ofmultiple doses of INH- A21, a donor-selected human staphylococcal immuneglobulin in low birth weight infants(HRRC 02-466)Principal Investigator(s): Robin K. OhlsUniversity of New Mexico Clinical & Translational Science CenterRole: Principal Investigator

01/01/01 - 12/31/06 NIH M01 RR 00997/NCRR #1 UL1 TR000154-01A placebo-controlled study evaluating recombinant erythropoietin to reduce bloodtransfusions in neonates requiring surgery(HRRC 01-160)Principal Investigator(s): Robin K. OhlsUniversity of New Mexico Clinical & Translational Science CenterRole: Principal Investigator

07/01/00 - 06/30/02 The Efficacy of Recombinant Erythropoietin in Infants with Congenital HeartDiseasePrincipal Investigator(s): Robin K. OhlsAmerican Heart AssociationRole: Principal Investigator

01/01/99 - 12/31/02 NIH M01 RR 00997/NCRR #1 UL1 TR000154-01The efficacy of recombinant erythropoietin in infants with congenital heart disease(HRRC 99-385)Principal Investigator(s): Robin K. OhlsUniversity of New Mexico Clinical & Translational Science CenterRole: Principal Investigator

07/01/98 - 12/31/99 The vascular response to erythropoietin in preterm infantsPrincipal Investigator(s): Robin K. OhlsAmerican Heart AssociationRole: Principal Investigator

11/01/97 - 12/31/98 Effects of G-CSF on cord blood neutrophil response to LPSPrincipal Investigator(s): Robin K. OhlsUniversity of New Mexico Health Sciences Center Research Allocation CommitteeRole: Principal Investigator

05/01/97 - 06/30/01 Network GrantEpo administration to preterm infantsPrincipal Investigator(s): Robin K. OhlsEunice Kennedy Shriver National Institute of Child Health and HumanDevelopmentRole: Principal Investigator

Ohls, Page 10

05/01/97 - 09/30/97 Institutional Development Award (IDeA)Effects of granulocyte-colony stimulating factor on term and preterm cord bloodneonatal neutrophil adhesive phenotypePrincipal Investigator(s): Robin K. OhlsNational Institutes of HealthRole: Principal Investigator

05/01/96 - 06/30/98 Investigator-initiated Clinical GrantEffects of G-CSF in the treatment of late-onset neonatal sepsisPrincipal Investigator(s): Robin K. OhlsAmgen Inc.Role: Principal Investigator

01/01/96 - 12/31/02 NIH M01 RR 00997/NCRR #1 UL1 TR000154-01The molecular and biologic basis of erythropoietin regulation in the anemia ofprematurity(HRRC 96-260)Principal Investigator(s): Robin K. OhlsUniversity of New Mexico Clinical & Translational Science CenterRole: Principal Investigator

01/01/96 - 12/31/02 NIH M01 RR 00997/NCRR #1 UL1 TR000154-01Effects of granulocyte-colony stimulating factor on term and preterm cord bloodneonatal neutrophil adhesive phenotype(HRRC 96-002)Principal Investigator(s): Robin K. OhlsUniversity of New Mexico Clinical & Translational Science CenterRole: Principal Investigator

01/01/96 - 12/31/01 NIH M01 RR 00997/NCRR #1 UL1 TR000154-01The effects of erythropoietin (Epo) on the transfusion requirements of preterminfants ≤1250 grams: a multicenter, randomized, double-masked, placebocontrolled study(HRRC 96-261)Principal Investigator(s): Robin K. OhlsUniversity of New Mexico Clinical & Translational Science CenterRole: Principal Investigator

01/01/96 - 12/31/01 NIH M01 RR 00997/NCRR #1 UL1 TR000154-01The effects of human recombinant thrombopoietin (TPO) on growth ofmegakaryocyte colonies from cord blood of preterm thrombocytopenic neonatesand assessment of their cord serum TPO concentrations(HRRC 96-402)Principal Investigator(s): Robin K. OhlsUniversity of New Mexico Clinical & Translational Science CenterRole: Principal Investigator

01/01/96 - 12/31/98 NIH M01 RR 00997/NCRR #1 UL1 TR000154-01Endothelin concentrations in preterm infants treated with human recombinanterythropoietin(HRRC 96-155)Principal Investigator(s): Robin K. OhlsUniversity of New Mexico Clinical & Translational Science CenterRole: Principal Investigator

Ohls, Page 11

01/01/96 - 12/31/97 NIH M01 RR 00997/NCRR #1 UL1 TR000154-01A multicenter, double-blind, randomized, placebo-controlled safety and efficacystudy of Filgrastim (r-metHuG-CSF) in the treatment of late-onset neonatal sepsis(HRRC 96-088)Principal Investigator(s): Robin K. OhlsUniversity of New Mexico Clinical & Translational Science CenterRole: Principal Investigator

01/01/96 - 12/31/97 NIH M01 RR 00997/NCRR #1 UL1 TR000154-01Responsiveness to recombinant human erythropoietin of erythroid progenitorsfrom cord blood of preterm infants ≤1000 grams(HRRC 96-003)Principal Investigator(s): Robin K. OhlsUniversity of New Mexico Clinical & Translational Science CenterRole: Principal Investigator

01/01/95 - 12/31/02 NIH M01 RR 00997/NCRR #1 UL1 TR000154-01A multi-centered, randomized, double-blind, placebo-controlled trial ofrecombinant granulocyte colony stimulating factor (G-CSF) administration to treatneutropenia in term and preterm infants(HRRC 95-160)Principal Investigator(s): Robin K. OhlsUniversity of New Mexico Clinical & Translational Science CenterRole: Principal Investigator

01/01/95 - 12/31/00 NIH M01 RR 00997/NCRR #1 UL1 TR000154-01Erythropoietin production by the mid-trimester fetal kidney(HRRC 95-261)Principal Investigator(s): Robin K. OhlsUniversity of New Mexico Clinical & Translational Science CenterRole: Principal Investigator

01/01/95 - 12/31/96 NIH M01 RR 00997/NCRR #1 UL1 TR000154-01The effects of erythropoietin on the transfusion requirements of extremely lowbirth weight infants (≤750 grams): a randomized, double-blind, placebo controlledtrial(HRRC 95-159)Principal Investigator(s): Robin K. OhlsUniversity of New Mexico Clinical & Translational Science CenterRole: Principal Investigator

01/01/94 - 12/31/95 Telethon AwardPrincipal Investigator(s): Robin K. OhlsChildren's Miracle Network HospitalsRole: Principal Investigator

01/01/94 - 12/31/94 Telethon AwardPrincipal Investigator(s): Robin K. OhlsChildren's Miracle Network HospitalsRole: Principal Investigator

01/01/93 - 12/31/94 DSR Faculty AwardPrincipal Investigator(s): Robin K. OhlsUniversity of FloridaRole: Principal Investigator

Ohls, Page 12

01/01/93 - 12/31/93 Telethon AwardPrincipal Investigator(s): Robin K. OhlsChildren's Miracle Network HospitalsRole: Principal Investigator

07/01/92 - 07/31/97 Regulation Of Erythropoiesis In The Fetus And Neonate.Principal Investigator(s): Robin K. OhlsDirect Costs: $71,050 Total Costs: $76,734National Institute of Child Health and Human DevelopmentRole: Principal Investigator

TEACHING RESPONSIBILITIES/ASSIGNMENTSCourse LecturesJune 1994 Invited Lecturer, Neonatal Advanced Physiology Course, University of Florida

College of Medicine, Epogen use in the neonate. Long term Management of theNeonate

Trainee SupervisionFaculty2019 - Present clinical research mentor, Belinda Chan, University of Utah, Clinical research

mentor/advisorTrainee's Current Career Activities: Clinical research grant to evaluate bedsideultrasound to determine respiratory distress syndrome in preterm infants

2018 - Present research mentor/career advisor, Jessie Maxwell, University of New Mexico,Advised Dr Maxwell on grant writing, translational research; career guidance;collaboration on NIH grant

2015 - Present Advisor/Mentor, Tara DuPont, University of Utah, Faculty research mentor forclinical research on ESAs for mild neonatal encephalopathyTrainee's Current Career Activities: Associate Professor, Pediatrics

Intern2015 - 2020 advisor/research mentor, Ryan Kiser, University of New Mexico, Advisor during

medical school, advisor and research mentor during Pediatric Residency, workedon project that was presented at WSPR and PAS.Trainee's Current Career Activities: Completing residency

Fellow2019 - Present clinical research mentor, Michelle Yang, University of Utah, Transitioning from

fellow to new faculty, will assist with career plans to perform clinical research,obtain further trainingTrainee's Current Career Activities: Third year fellow

2017 - 2020 Program Director; research mentor, Uche Nwokidu-Aderabigbe, University ofNew Mexico, Research mentor for Dr. Nwokidu, supervising research project forfellowshipTrainee's Current Career Activities: Completing 3rd year fellowship

Ohls, Page 13

2015 - 2018 Program Director; research mentor, Catherine Milner, University of New Mexico,clinical research mentor for fellow's research projectTrainee's Current Career Activities: Private practice in Oaklahoma

Resident1996 - 2017 research mentor/career advisor, University of New Mexico, Mentored the

following medical students/residents/fellows and guided their laboratory andclinical research projects from 1996 through 2017: Mark Bellis; Alison Cogar; KariGard; Christine Criscuolo; Cyrus Ali; Ryann Bierer; Heather McKnight; ScottSnyder; Michael Rowe; Ryan Hodnick; Shrena Patel; Vinit Manuel; NaderBishara; Sally Vendor; Gene LaMonica; Christine Chen; Irene Ma; Jennifer Rael;Nichole Veitenheimer; Brian Melloy; Katie Sanchez; Umar Malik; Eileen Stewart;Alesha Dye; Claire Wilson; Scott Rossol; Sanaa Nagji; Denisha McCall; ChristinaDavidson; Michael Yao; Priya Shah; Jordan Foreman; Mirana Aragon, Amy NimTrainee's Current Career Activities: Students and residents have gone on tofellowships and faculty positions at academic institutions

MD, PhD2017 - 2020 clinical research mentor, Sydney Cooper, University of New Mexico, clinical

research mentor for medical student research project; presented at WSPR in 2019;winner of the Abbott Nutrition Medical Student Research AwardTrainee's Current Career Activities: Surgical Residency

2017 - 2020 clinical research mentor, Clare Batty, University of New Mexico, clinical researchmentor for medical student research project; presented at WSPR in 2019; winner ofthe Abbott Nutrition Medical Student Research AwardTrainee's Current Career Activities: Pediatric residency

Internal Teaching Experience2011 Erythropoiesis stimulating agents as neuroprotectants in preterm infants, Hot

Topics, University of New Mexico School of Medicine (Invited)2006 Darbepoetin: Biology, Pharmacology, and Clinical use in Neonates, 8th Annual

University of New Mexico School of Medicine Hematology Oncology Conference(Invited)

1997 How to give an excellent presentation, Creative Endeavors Conference, Universityof New Mexico School of Medicine (Invited)

1996 How to choose a mentor in research, Creative Endeavors Conference, University ofNew Mexico School of Medicine (Invited)

PEER-REVIEWED JOURNAL ARTICLES1. Gantz MG, Carlo WA, Finer NN, Rich W, Faix RG, Yoder BA, Walsh MC, Newman NS, Laptook

A, Schibler K, Das A, Higgins RD; SUPPORT Study Group of the Eunice Kennedy ShriverNational Institute of Child Health and Human Development Neonatal Research Network. (2020).Achieved Oxygen Saturations and Retinopathy of Prematurity in Extreme Preterms. Arch Dis ChildFetal Neonatal Ed, 105(2), 138-144.

2. Harmon HM, Jensen EA, Tan S, Chaudhary AS, Slaughter JL, Bell EF, Wyckoff MH, HensmanAM, Sokol GM, DeMauro SB; Eunice Kennedy Shriver National Institute of Child Health andHuman Development Neonatal Research Network (2020). Timing of Postnatal Steroids for

Ohls, Page 14

Bronchopulmonary Dysplasia: Association With Pulmonary and Neurodevelopmental Outcomes. JPerinatol.

3. 5. Selewski DT, Gist KM, Nathan AT, Goldstein SL, Boohaker LJ, Akcan-Arikan A, BonacheaEM, Hanna M, Joseph C, Mahan JD, Mammen C, Nada A, Reidy K, Staples A, Wintermark P,Griffin R, Askenazi DJ, Guillet R; Neonatal Kidney Collaborative. (2020). The Impact of FluidBalance on Outcomes in Premature Neonates: A Report From the AWAKEN Study Group. PediatrRes, 87(3), 550-557.

4. Brumbaugh JE, Bell EF, Grey SF, DeMauro SB, Vohr BR, Harmon HM, Bann CM, Rysavy MA,Logan JW, Colaizy TT, Peralta-Carcelen MA, McGowan EC, Duncan AF, Stoll BJ, Das A, HintzSR; Eunice Kennedy Shriver National Institute of Child Health and Human Development NeonatalResearch Network. (2020). Behavior Profiles at 2 Years for Children Born Extremely Preterm WithBronchopulmonary Dysplasia. J Pediatr.

5. Juul SE, Comstock BA, Wadhawan R, Mayock DE, Courtney SE, Robinson T, Ahmad KA,Bendel-Stenzel E, Baserga M, LaGamma EF, Downey LC, Rao R, Fahim N, Lampland A, Frantz IiiID, Khan JY, Weiss M, Gilmore MM, Ohls RK, Srinivasan N, Perez JE, McKay V, Vu PT, LoweJ, Kuban K, O'Shea TM, Hartman AL, Heagerty PJ, PENUT Trial Consortium. (2020). ARandomized Trial of Erythropoietin for Neuroprotection in Preterm Infants. N Engl J Med, 382(3),233-243.

6. Ahmad KA, Bennett MM, Juul SE, Ohls RK, Clark RH, Tolia VN (2019). Utilization ofErythropoietin within the United States Neonatal Intensive Care Units from 2008 to 2017.(Epubahead of print) Am J Perinatol.

7. Maxwell JR, Ohls RK (2019). Update on Erythropoiesis-Stimulating Agents Administered toNeonates for Neuroprotection. Neoreviews, 20(11), e622-e635.

8. Foglia EE, Carper B, Gantz M, DeMauro SB, Lakshminrusimha S, Walsh M, Schmidt B; EuniceKennedy Shriver National Institute of Child Health and Human Development Neonatal ResearchNetwork (2019). Association Between Policy Changes for Oxygen Saturation Alarm Settings andNeonatal Morbidity and Mortality in Infants Born Very Preterm. J Pediatr, 209, 17-22.

9. Möbius MA, Freund D, Vadivel A, Koss S, McConaghy S, Ohls RK, Rüdiger M, Thébaud B(2019). Oxygen Disrupts Human Fetal Lung Mesenchymal Cells. Implications forBronchopulmonary Dysplasia. Am J Respir Cell Mol Biol, 60(5), 592-600.

10. Charlton JR, Boohaker L, Askenazi D, Brophy P, D’Angio C, Fuloria M, Gien J, Grifin R,Hingorani S, Ingraham S, Mian A, Ohls RK, Rastogi S, Rhee CJ, Revenis M, Sarkar A, Smith A,Starr M, Kent AL (2019). Incidence and Risk Factors of Early Onset Neonatal AKI: Results fromthe AWAKEN Study (Assessment of Worldwide Acute Kidney Injury Epidemiology in Neonates).Clin J Am Soc Nephrol, 14(2), 184-195.

11. Charlton JR, Boohaker L, Askenazi D, Brophy PD, D'Angio C, Fuloria M, Gien J, Griffin R,Hingorani S, Ingraham S, Mian A, Ohls RK, Rastogi S, Rhee CJ, Revenis M, Sarkar S, Smith A,Starr M, Kent AL, Neonatal Kidney Collaborative. (2019). Incidence and Risk Factors of EarlyOnset Neonatal AKI. Clin J Am Soc Nephrol, 14(2), 184-195.

12. 6. Askenazi D, Abitbol C, Boohaker L, Griffin R, Raina R, Dower J, Davis TK, Ray PE, Perazzo S,DeFreitas M, Milner L, Ambalavanan N, Cole FS, Rademacher E, Zappitelli M, Mhanna M;Neonatal Kidney Collaborative. (2019). Optimizing the AKI Definition During First PostnatalWeek Using Assessment of Worldwide Acute Kidney Injury Epidemiology in Neonates(AWAKEN) Cohort. Pediatr Res, 85(3), 329-338.

13. Charlton JR, Boohaker L, Askenazi D, Brophy PD, Fuloria M, Gien J, Griffin R, Hingorani S,Ingraham S, Mian A, Ohls RK, Rastogi S, Rhee CJ, Revenis M, Sarkar S, Starr M, Kent AL,Neonatal Kidney Collaborative (NKC). (2019). Late onset neonatal acute kidney injury: resultsfrom the AWAKEN Study. Pediatr Res, 85(3), 339-348.

Ohls, Page 15

14. Selewski DT, Akcan-Arikan A, Bonachea EM, Gist KM, Goldstein SL, Hanna M, Joseph C, MahanJD, Nada A, Nathan AT, Reidy K, Staples A, Wintermark P, Boohaker LJ, Griffin R, Askenazi DJ,Guillet R; Neonatal Kidney Collaborative. (2019). The Impact of Fluid Balance on Outcomes inCritically Ill Near-Term/Term Neonates: A Report From the AWAKEN Study Group. Pediatr Res,85(1), 79-85.

15. McGowan EC, Laptook AR, Lowe J, Peralta-Carcelen M, Chowdhury D, Higgins RD, Hintz SR,Vohr BR; Eunice Kennedy Shriver National Institute of Child Health and Human DevelopmentNeonatal Research Network (2019). Developmental Outcomes of Extremely Preterm Infants With aNeed for Child Protective Services Supervision. J Pediatr, 215, 41-49.

16. Duncan AF, Bann CM, Dempsey A, Peralta-Carcelen M, Hintz S; Eunice Kennedy Shriver NationalInstitute of Child Health and Development Neonatal Research Network. (2019). Behavioral Deficitsat 18-22 Months of Age Are Associated With Early Cerebellar Injury and Cognitive and LanguagePerformance in Children Born Extremely Preterm. J Pediatr, 204, 148-156.

17. Shankaran S, Bell EF, Laptook AR, Saha S, Newman NS, Kazzi SNJ, Barks J, Stoll BJ, Bara R,Gabrio J, Childs K, Das A, Higgins RD, Carlo WA, Sánchez PJ, Carlton DP, Pavageau L, MalcolmWF, D'Angio CT, Ohls RK, Poindexter BB, Sokol GM, Van Meurs KP, Colaizy TT, Khmour A,Puopolo KM, Garg M, Walsh MC, Eunice Kennedy Shriver National Institute of Child Health, andHuman Development Neonatal Research Network. (2019). Weaning of Moderately Preterm Infantsfrom the Incubator to the Crib: A Randomized Clinical Trial. J Pediatr, 204, 96-102.e4.

18. Shah AR, Wilfond BS, Silvia A, Hancuch K, Woodrum D, Heagerty P, Ohls RK, Courtney SE,Frantz ID, Gogcu S, Bishop CE, Ahmad KA, Kathen C, Juul S, PENUT Neonatal Informed ConsentWorking Group. (2018). Informed consent for a neonatal clinical trial: parental experiences andperspectives. J Perinatol, 38(7), 865-872.

19. 11. Harer MW, Askenazi DJ, Boohaker LJ, Carmody JB, Griffin RL, Guillet R, Selewski DT,Swanson JR, Charlton JR; Neonatal Kidney Collaborative (NKC) (2018). Association BetweenEarly Caffeine Citrate Administration and Risk of Acute Kidney Injury in Preterm Neonates:Results From the AWAKEN Study. JAMA Pediatr, 172(6), 599.

20. Kraut EJ, Boohaker LJ, Askenazi DJ, Fletcher J, Kent AL, Ohls RK (2018). Incidence of neonatalhypertension from a large multicenter study [Assessment of Worldwide Acute Kidney InjuryEpidemiology in Neonates-AWAKEN].LID - 10.1038/s41390-018-0018-8 [doi].(Epub ahead ofprint) Pediatr Res.

21. Bajaj M, Natarajan G, Shankaran S, Wyckoff M, Laptook AR, Bell EF, Stoll BJ, Carlo WA, VohrBR, Saha S, Van Meurs KP, Sanchez PJ, D'Angio CT, Higgins RD, Das A, Newman N, Walsh MC,Ohls RK (2018). Delivery Room Resuscitation and Short-Term Outcomes in Moderately PretermInfants. J Pediatr, 195, 33-38.e2.

22. Sarkar S, Shankaran S, Barks J, Do BT, Laptook AR, Das A, Ambalavanan N, Van Meurs KP, BellEF, Sanchez PJ, Hintz SR, Wyckoff MH, Stoll BJ, Carlo WA, Ohls RK (2018). Outcome ofPreterm Infants with Transient Cystic Periventricular Leukomalacia on Serial Cranial Imaging Upto Term Equivalent Age. J Pediatr, 195, 59-65.e3.

23. Natarajan G, Shankaran S, Saha S, Laptook A, Das A, Higgins R, Stoll BJ, Bell EF, Carlo WA,D'Angio C, DeMauro SB, Sanchez P, Van Meurs K, Vohr B, Newman N, Hale E, Walsh M, OhlsRK (2018). Antecedents and Outcomes of Abnormal Cranial Imaging in Moderately PretermInfants. J Pediatr, 195, 66-72.e3.

24. Gasparovic C, Caprihan A, Yeo RA, Phillips J, Lowe JR, Campbell R, Ohls RK (2018). Thelong-term effect of erythropoiesis stimulating agents given to preterm infants: a proton magneticresonance spectroscopy study on neurometabolites in early childhood. Pediatr Radiol, 48(3),374-382.

25. Laptook AR, Bell EF, Shankaran S, Boghossian NS, Wyckoff MH, Kandefer S, Walsh M, Saha S,Ohls, Page 16

Higgins R, Ohls RK (2018). Admission Temperature and Associated Mortality and Morbidityamong Moderately and Extremely Preterm Infants. J Pediatr, 192, 53-59.e2.

26. James J, Munson D, DeMauro SB, Langer JC, Dworetz AR, Natarajan G, Bidegain M, Fortney CA,Seabrook R, Vohr BR, Tyson JE, Bell EF, Poindexter BB, Shankaran S, Higgins RD, Das A, StollBJ, Kirpalani H, Ohls RK (2017). Outcomes of Preterm Infants following Discussions aboutWithdrawal or Withholding of Life Support. J Pediatr, 190, 118-123.e4.

27. Phillips J, Yeo RA, Caprihan A, Cannon DC, Patel S, Winter S, Steffen M, Campbell R, WiedmeierS, Baker S, Gonzales S, Lowe J, Ohls RK (2017). Neuroimaging in former preterm children whoreceived erythropoiesis stimulating agents. Pediatr Res, 82(4), 685-690.

28. Chawla S, Natarajan G, Shankaran S, Carper B, Brion LP, Keszler M, Carlo WA, Ambalavanan N,Gantz MG, Das A, Finer N, Goldberg RN, Cotten CM, Higgins RD, Ohls RK (2017). Markers ofSuccessful Extubation in Extremely Preterm Infants, and Morbidity After Failed Extubation. JPediatr, 189, 113-119.e2.

29. Jensen EA, Dysart KC, Gantz MG, Carper B, Higgins RD, Keszler M, Laughon MM, PoindexterBB, Stoll BJ, Walsh MC, Schmidt B, Ohls RK (2017). Association between Use of ProphylacticIndomethacin and the Risk for Bronchopulmonary Dysplasia in Extremely Preterm Infants. JPediatr, 186, 34-40.e2.

30. An G, Ohls RK, Christensen RD, Widness JA, Mock DM, Veng-Pedersen P (2017). PopulationPharmacokinetics of Darbepoetin in Infants Following Single Intravenous and SubcutaneousDosing. J Pharm Sci, 106(6), 1644-1649.

31. Lowe JR, Rieger RE, Moss NC, Yeo RA, Winter S, Patel S, Phillips J, Campbell R, Baker S,Gonzales S, Ohls RK (2017). Impact of Erythropoiesis-Stimulating Agents on Behavioral Measuresin Children Born Preterm. J Pediatr, 184, 75-80.e1.

32. Younge N, Goldstein RF, Bann CM, Hintz SR, Patel RM, Smith PB, Bell EF, Rysavy MA, DuncanAF, Vohr BR, Das A, Goldberg RN, Higgins RD, Cotten CM; Eunice Kennedy Shriver NationalInstitute of Child Health and Human Development Neonatal Research Network. (2017). Survivaland Neurodevelopmental Outcomes Among Periviable Infants. N Engl J Med, 376(7), 617-628.

33. Younge N, Goldstein RF, Bann CM, Hintz SR, Patel RM, Smith PB, Bell EF, Rysavy MA, DuncanAF, Vohr BR, Das A, Goldberg RN, Higgins RD, Cotten CM, Ohls RK (2017). Survival andNeurodevelopmental Outcomes among Periviable Infants. N Engl J Med, 376(7), 617-628.

34. Mani S, Cannon D, Ohls R, Oprea T, Mathias S, Ballard K, Ursu O, Bologa C (2017). Proteinbiomarker druggability profiling. J Biomed Inform, 66, 241-247.

35. MohanKumar K, Namachivayam K, Ho TT, Torres BA, Ohls RK, Maheshwari A (2017).Cytokines and growth factors in the developing intestine and during necrotizing enterocolitis. SeminPerinatol, 41(1), 52-60.

36. Jetton JG, Boohaker LJ, Sethi SK, Wazir S, Rohatgi S, Soranno DE, Chishti AS, Woroniecki R,Mammen C, Swanson JR, Sridhar S, Wong CS, Kupferman JC, Griffin RL, Askenazi DJ; NeonatalKidney Collaborative (NKC) (2017). Incidence and Outcomes of Neonatal Acute Kidney Injury(AWAKEN): A Multicentre, Multinational, Observational Cohort Study. Lancet Child AdolescHealth, 1(3), 184-194.

37. Lowe JR, Rieger RE, Moss NC, Yeo RA, Winter S, Patel S, Phillips J, Campbell R, Baker S,Gonzales S, Ohls RK. (2017). Impact of Erythropoiesis-Stimulating Agents on BehavioralMeasures in Children Born Preterm. J Pediatr, 184, 75-80.

38. Ohls RK (2017). Indications for Red Cell Transfusions in Preterm Infants. UpToDate.

39. Navarrete CT, Wrage LA, Carlo WA, Walsh MC, Rich W, Gantz MG, Das A, Schibler K, NewmanNS, Piazza AJ, Poindexter BB, Shankaran S, Sanchez PJ, Morris BH, Frantz ID 3rd, Van MeursKP, Cotten CM, Ehrenkranz RA, Bell EF, Watterberg KL, Higgins RD, Duara S, Ohls RK (2016).

Ohls, Page 17

Growth Outcomes of Preterm Infants Exposed to Different Oxygen Saturation Target Ranges fromBirth. J Pediatr, 176, 62-68.e4.

40. Ohls RK, Cannon DC, Phillips J, Caprihan A, Patel S, Winter S, Steffen M, Yeo RA, Campbell R,Wiedmeier S, Baker S, Gonzales S, Lowe J (2016). Preschool Assessment of Preterm InfantsTreated With Darbepoetin and Erythropoietin. Pediatrics, 137(3), e20153859.

41. McConaghy S, Manuel V, Nagji S, Ohls RK (2016). Epsilon globin gene expression in developinghuman fetal tissues. J Neonatal Perinatal Med, 9(1), 91-7.

42. Ohls RK (2016). Indications for Red Cell Transfusions in Preterm Infants. UpToDate.

43. Jetton JG, Guillet R, Askenazi DJ, Dill L, Jacobs J, Kent AL, Selewski DT, Abitbol CL, Kaskel FJ,Mhanna MJ, Ambalavanan N, Charlton JR, Ohls RK (2016). Assessment of Worldwide AcuteKidney Injury Epidemiology in Neonates: Design of a Retrospective Cohort Study. Front Pediatr, 4, 68.

44. Alphonse RS, Vadivel A, Zhong S, McConaghy S, Ohls R, Yoder MC, Thebaud B (2015). Theisolation and culture of endothelial colony-forming cells from human and rat lungs. Nat Protoc, 10(11), 1697-708.

45. Baserga MC, Beachy JC, Roberts JK, Ward RM, DiGeronimo RJ, Walsh WF, Ohls RK, AndersonJ, Mayock DE, Juul SE, Christensen RD, Loertscher MC, Stockmann C, Sherwin CM, SpigarelliMG, Yoder BA (2015). Darbepoetin administration to neonates undergoing cooling forencephalopathy: a safety and pharmacokinetic trial. Pediatr Res, 78(3), 315-22.

46. Patel S, Ohls RK (2015). Darbepoetin Administration in Term and Preterm Neonates. ClinPerinatol, 42(3), 557-66.

47. Ma IT, McConaghy S, Namachivayam K, Halloran BA, Kurundkar AR, MohanKumar K,Maheshwari A, Ohls RK (2015). VEGF mRNA and protein concentrations in the developinghuman eye. Pediatr Res, 77(4), 500-5.

48. Thebaud B, Rajesh Alphonse, Arul Vadivel, Shumei Zhong, Suzanne McConaghy, Ohls RK, andMervin Yoder. (2015). The Isolation and Culture of Endothelial Colony-Forming Cells FromHuman and Rat Lungs. Nat Protoc, 10(11), 1697-708.

49. Ohls RK, Christensen RD, Widness JA, Juul SE (2015). Erythropoiesis Stimulating AgentsDemonstrate Safety and Show Promise as Neuroprotective Agents in Neonates. J Pediatr, 167(1),10-2.

50. Ohls RK (2015). Indications for Red Cell Transfusions in Preterm Infants. UpToDate.

51. Sood BG, Keszler M, Garg M, Klein JM, Ohls R, Ambalavanan N, Cotten CM, Malian M, SanchezPJ, Lakshminrusimha S, Nelin LD, Van Meurs KP, Bara R, Saha S, Das A, Wallace D, Higgins RD,Shankaran S (2014). Inhaled PGE1 in neonates with hypoxemic respiratory failure: two pilotfeasibility randomized clinical trials. Trials, 15, 486.

52. Lowe J, Erickson SJ, MacLean P, Duvall SW, Ohls RK, Duncan AF (2014). Associations betweenmaternal scaffolding and executive functioning in 3 and 4 year olds born very low birth weight andnormal birth weight. Early Hum Dev, 90(10), 587-93.

53. Stevens TP, Finer NN, Carlo WA, Szilagyi PG, Phelps DL, Walsh MC, Gantz MG, Laptook AR,Yoder BA, Faix RG, Newman JE, Das A, Do BT, Schibler K, Rich W, Newman NS, EhrenkranzRA, Peralta-Carcelen M, Vohr BR, Wilson-Costello DE, Yolton K, Heyne RJ, Evans PW, VaucherYE, Adams-Chapman I, McGowan EC, Bodnar A, Pappas A, Hintz SR, Acarregui MJ, Fuller J,Goldstein RF, Bauer CR, O'Shea TM, Myers GJ, Higgins RD, Ohls RK (2014). Respiratoryoutcomes of the surfactant positive pressure and oximetry randomized trial (SUPPORT). J Pediatr,165(2), 240-249.e4.

54. Morriss FH Jr, Saha S, Bell EF, Colaizy TT, Stoll BJ, Hintz SR, Shankaran S, Vohr BR, Hamrick

Ohls, Page 18

SE, Pappas A, Jones PM, Carlo WA, Laptook AR, Van Meurs KP, Sanchez PJ, Hale EC, NewmanNS, Das A, Higgins RD, Ohls RK (2014). Surgery and neurodevelopmental outcome of verylow-birth-weight infants. JAMA Pediatr, 168(8), 746-54.

55. Ohls RK, Kamath-Rayne BD, Christensen RD, Wiedmeier SE, Rosenberg A, Fuller J, Lacy CB,Roohi M, Lambert DK, Burnett JJ, Pruckler B, Peceny H, Cannon DC, Lowe JR (2014). Cognitiveoutcomes of preterm infants randomized to darbepoetin, erythropoietin, or placebo. Pediatrics, 133(6), 1023-30.

56. Alphonse RS, Vadivel A, Fung M, Shelley WC, Critser PJ, Ionescu L, O'Reilly M, Ohls RK,McConaghy S, Eaton F, Zhong S, Yoder M, Thébaud B (2014). Existence, functional impairment,and lung repair potential of endothelial colony-forming cells in oxygen-induced arrested alveolargrowth. Circulation, 129(21), 2144-57.

57. Kennedy KA, Wrage LA, Higgins RD, Finer NN, Carlo WA, Walsh MC, Laptook AR, Faix RG,Yoder BA, Schibler K, Gantz MG, Das A, Newman NS, Phelps DL, Ohls RK (2014). Evaluatingretinopathy of prematurity screening guidelines for 24- to 27-week gestational age infants. JPerinatol, 34(4), 311-8.

58. Messier AM, Ohls RK (2014). Neuroprotective effects of erythropoiesis-stimulating agents in termand preterm neonates. Curr Opin Pediatr, 26(2), 139-45.

59. Boghossian NS, Hansen NI, Bell EF, Stoll BJ, Murray JC, Carey JC, Adams-Chapman I, ShankaranS, Walsh MC, Laptook AR, Faix RG, Newman NS, Hale EC, Das A, Wilson LD, Hensman AM,Grisby C, Collins MV, Vasil DM, Finkle J, Maffett D, Ball MB, Lacy CB, Bara R, Higgins RD,Ohls RK (2014). Mortality and morbidity of VLBW infants with trisomy 13 or trisomy 18.Pediatrics, 133(2), 226-35.

60. Ohls RK (2014). Indications for Red Cell Transfusions in Preterm Infants. UpToDate.

61. Lowe JR, Duncan AF, Bann CM, Fuller J, Hintz SR, Das A, Higgins RD, Watterberg KL; EuniceKennedy Shriver National Institute of Child Health and Human Development Neonatal ResearchNetwork. (2013). Early Working Memory as a Racially and Ethnically Neutral Measure of Outcomein Extremely Preterm Children at 18-22 Months. Early Hum Dev, 89(12), 1055-61.

62. Lowe JR, Duncan AF, Bann CM, Fuller J, Hintz SR, Das A, Higgins RD, Watterberg KL, Ohls RK(2013). Early working memory as a racially and ethnically neutral measure of outcome in extremelypreterm children at 18-22 months. Early Hum Dev, 89(12), 1055-61.

63. Adams-Chapman I, Bann CM, Vaucher YE, Stoll BJ, Ohls RK (2013). Association betweenfeeding difficulties and language delay in preterm infants using Bayley Scales of InfantDevelopment-Third Edition. J Pediatr, 163(3), 680-5.e1-3.

64. De Jesus LC, Pappas A, Shankaran S, Li L, Das A, Bell EF, Stoll BJ, Laptook AR, Walsh MC, HaleEC, Newman NS, Bara R, Higgins RD, Ohls RK (2013). Outcomes of small for gestational ageinfants born at <27 weeks' gestation. J Pediatr, 163(1), 55-60.e1-3.

65. Ohls RK, Christensen RD, Kamath-Rayne BD, Rosenberg A, Wiedmeier SE, Roohi M, Lacy CB,Lambert DK, Burnett JJ, Pruckler B, Schrader R, Lowe JR (2013). A randomized, masked,placebo-controlled study of darbepoetin alfa in preterm infants. Pediatrics, 132(1), e119-27.

66. Alleman BW, Bell EF, Li L, Dagle JM, Smith PB, Ambalavanan N, Laughon MM, Stoll BJ,Goldberg RN, Carlo WA, Murray JC, Cotten CM, Shankaran S, Walsh MC, Laptook AR, EllsburyDL, Hale EC, Newman NS, Wallace DD, Das A, Higgins RD, Ohls RK (2013). Individual andcenter-level factors affecting mortality among extremely low birth weight infants. Pediatrics, 132(1), e175-84.

67. Adams-Chapman I, Hansen NI, Shankaran S, Bell EF, Boghossian NS, Murray JC, Laptook AR,Walsh MC, Carlo WA, Sanchez PJ, Van Meurs KP, Das A, Hale EC, Newman NS, Ball MB,Higgins RD, Stoll BJ, Ohls RK (2013). Ten-year review of major birth defects in VLBW infants.

Ohls, Page 19

Pediatrics, 132(1), 49-61.68. Ohls RK (2013). Why study erythropoietin in preterm infants? Acta Paediatr, 102(6), 567-8.

69. 116. Wynn JL, Hansen NI, Das A, Cotten CM, Goldberg RN, Sánchez PJ, Bell EF, Van Meurs KP,Carlo WA, Laptook AR, Higgins RD, Benjamin DK Jr, Stoll BJ; Eunice Kennedy Shriver NationalInstitute of Child Health and Human Development Neonatal Research Network. (2013). EarlySepsis Does Not Increase the Risk of Late Sepsis in Very Low Birth Weight Neonates. J Pediatr,162(5), 942-8.

70. Wynn JL, Hansen NI, Das A, Cotten CM, Goldberg RN, Sanchez PJ, Bell EF, Van Meurs KP,Carlo WA, Laptook AR, Higgins RD, Benjamin DK Jr, Stoll BJ, Ohls RK (2013). Early sepsisdoes not increase the risk of late sepsis in very low birth weight neonates. J Pediatr, 162(5),942-8.e1-3.

71. Payne AH, Hintz SR, Hibbs AM, Walsh MC, Vohr BR, Bann CM, Wilson-Costello DE, Ohls RK(2013). Neurodevelopmental outcomes of extremely low-gestational-age neonates with low-gradeperiventricular-intraventricular hemorrhage. JAMA Pediatr, 167(5), 451-9.

72. Ohls RK (2013). Indications for Red Cell Transfusions in Preterm Infants. UpToDate.

73. Vaucher YE, Peralta-Carcelen M, Finer NN, Carlo WA, Gantz MG, Walsh MC, Laptook AR,Yoder BA, Faix RG, Das A, Schibler K, Rich W, Newman NS, Vohr BR, Yolton K, Heyne RJ,Wilson-Costello DE, Evans PW, Goldstein RF, Acarregui MJ, Adams-Chapman I, Pappas A, HintzSR, Poindexter B, Dusick AM, McGowan EC, Ehrenkranz RA, Bodnar A, Bauer CR, Fuller J,O'Shea TM, Myers GJ, Higgins RD, Ohls RK (2012). Neurodevelopmental outcomes in the earlyCPAP and pulse oximetry trial. N Engl J Med, 367(26), 2495-504.

74. Newman JE, Bann CM, Vohr BR, Dusick AM, Higgins RD, Ohls RK (2012). Improving theNeonatal Research Network annual certification for neurologic examination of the 18-22 monthchild. J Pediatr, 161(6), 1041-6.

75. Vohr BR, Stephens BE, Higgins RD, Bann CM, Hintz SR, Das A, Newman JE, Peralta-Carcelen M,Yolton K, Dusick AM, Evans PW, Goldstein RF, Ehrenkranz RA, Pappas A, Adams-Chapman I,Wilson-Costello DE, Bauer CR, Bodnar A, Heyne RJ, Vaucher YE, Dillard RG, Acarregui MJ,McGowan EC, Myers GJ, Fuller J, Ohls RK (2012). Are outcomes of extremely preterm infantsimproving? Impact of Bayley assessment on outcomes. J Pediatr, 161(2), 222-8.e3.

76. Greenberg RG, Benjamin DK Jr, Gantz MG, Cotten CM, Stoll BJ, Walsh MC, Sanchez PJ,Shankaran S, Das A, Higgins RD, Miller NA, Auten KJ, Walsh TJ, Laptook AR, Carlo WA,Kennedy KA, Finer NN, Duara S, Schibler K, Ehrenkranz RA, Van Meurs KP, Frantz ID 3rd,Phelps DL, Poindexter BB, Bell EF, O'Shea TM, Watterberg KL, Goldberg RN, Smith PB, OhlsRK (2012). Empiric antifungal therapy and outcomes in extremely low birth weight infants withinvasive candidiasis. J Pediatr, 161(2), 264-9.e2.

77. De Jesus LC, Pappas A, Shankaran S, Kendrick D, Das A, Higgins RD, Bell EF, Stoll BJ, LaptookAR, Walsh MC, Ohls RK (2012). Risk factors for post-neonatal intensive care unit dischargemortality among extremely low birth weight infants. J Pediatr, 161(1), 70-4.e1-2.

78. Batton BJ, Li L, Newman NS, Das A, Watterberg KL, Yoder BA, Faix RG, Laughon MM, VanMeurs KP, Carlo WA, Higgins RD, Walsh MC, Ohls RK (2012). Feasibility study of early bloodpressure management in extremely preterm infants. J Pediatr, 161(1), 65-9.e1.

79. Duncan AF, Watterberg KL, Nolen TL, Vohr BR, Adams-Chapman I, Das A, Lowe J, Ohls RK(2012). Effect of ethnicity and race on cognitive and language testing at age 18-22 months inextremely preterm infants. J Pediatr, 160(6), 966-71.e2.

80. Ohls RK, Roohi M, Peceny HM, Schrader R, Bierer R (2012). A randomized, masked study ofweekly erythropoietin dosing in preterm infants. J Pediatr, 160(5), 790-5.e1.

Ohls, Page 20

81. Shane AL, Hansen NI, Stoll BJ, Bell EF, Sanchez PJ, Shankaran S, Laptook AR, Das A, WalshMC, Hale EC, Newman NS, Schrag SJ, Higgins RD, Ohls RK (2012). Methicillin-resistant andsusceptible Staphylococcus aureus bacteremia and meningitis in preterm infants. Pediatrics, 129(4),e914-22.

82. Rich W, Finer NN, Gantz MG, Newman NS, Hensman AM, Hale EC, Auten KJ, Schibler K, FaixRG, Laptook AR, Yoder BA, Das A, Shankaran S, Ohls RK (2012). Enrollment of extremely lowbirth weight infants in a clinical research study may not be representative. Pediatrics, 129(3), 480-4.

83. Lowe JR, Maclean PC, Caprihan A, Ohls RK, Qualls C, Vanmeter J, Phillips JP (2012).Comparison of cerebral volume in children aged 18-22 and 36-47 months born preterm and term. JChild Neurol, 27(2), 172-7.

84. Wynn JL, Tan S, Gantz MG, Das A, Goldberg RN, Adams-Chapman I, Stoll BJ, Shankaran S,Walsh MC, Auten KJ, Miller NA, Sanchez PJ, Higgins RD, Cotten CM, Smith PB, Benjamin DKJr, Ohls RK (2012). Outcomes following candiduria in extremely low birth weight infants. ClinInfect Dis, 54(3), 331-9.

85. Ohls RK (2012). Indications for Red Cell Transfusions in Preterm Infants. UpToDate.

86. Phillips JP, Montague EQ, Aragon M, Lowe JR, Schrader RM, Ohls RK, Caprihan A (2011).Prematurity affects cortical maturation in early childhood. Pediatr Neurol, 45(4), 213-9.

87. Laughon MM, Langer JC, Bose CL, Smith PB, Ambalavanan N, Kennedy KA, Stoll BJ, Buchter S,Laptook AR, Ehrenkranz RA, Cotten CM, Wilson-Costello DE, Shankaran S, Van Meurs KP, DavisAS, Gantz MG, Finer NN, Yoder BA, Faix RG, Carlo WA, Schibler KR, Newman NS, Rich W,Das A, Higgins RD, Walsh MC, Ohls RK (2011). Prediction of bronchopulmonary dysplasia bypostnatal age in extremely premature infants. Am J Respir Crit Care Med, 183(12), 1715-22.

88. Lowe J, Duvall SW, MacLean PC, Caprihan A, Ohls R, Qualls C, Phillips J (2011). Comparison ofstructural magnetic resonance imaging and development in toddlers born very low birth weight andfull-term. J Child Neurol, 26(5), 586-92.

89. Phillips JP, Ruhl D, Montague E, Gasparovic C, Caprihan A, Ohls RK, Schrader R, Lowe JR(2011). Anterior cingulate and frontal lobe white matter spectroscopy in early childhood of formervery LBW premature infants. Pediatr Res, 69(3), 224-9.

90. Maheshwari A, Kelly DR, Nicola T, Ambalavanan N, Jain SK, Murphy-Ullrich J, Athar M,Shimamura M, Bhandari V, Aprahamian C, Dimmitt RA, Serra R, Ohls RK (2011). TGF-β2suppresses macrophage cytokine production and mucosal inflammatory responses in the developingintestine. Gastroenterology, 140(1), 242-53.

91. Ohls RK (2011). Indications for Red Cell Transfusions in Preterm Infants. UpToDate.

92. Ohls RK (2011). The Biology of Hemoglobin. Neoreviews, 12, 29-38.

93. Boghossian NS, Hansen NI, Bell EF, Stoll BJ, Murray JC, Laptook AR, Shankaran S, Walsh MC,Das A, Higgins RD, Ohls RK (2010). Survival and morbidity outcomes for very low birth weightinfants with Down syndrome. Pediatrics, 126(6), 1132-40.

94. Waleh N, Hodnick R, Jhaveri N, McConaghy S, Dagle J, Seidner S, McCurnin D, Murray JC, OhlsR, Clyman RI (2010). Patterns of gene expression in the ductus arteriosus are related toenvironmental and genetic risk factors for persistent ductus patency. Pediatr Res, 68(4), 292-7.

95. Rich WD, Auten KJ, Gantz MG, Hale EC, Hensman AM, Newman NS, Finer NN, Ohls RK(2010). Antenatal consent in the SUPPORT trial: challenges, costs, and representative enrollment.Pediatrics, 126(1), e215-21.

96. Carlo WA, Finer NN, Walsh MC, Rich W, Gantz MG, Laptook AR, Yoder BA, Faix RG, Das A,Poole WK, Schibler K, Newman NS, Ambalavanan N, Frantz ID 3rd, Piazza AJ, Sanchez PJ,Morris BH, Laroia N, Phelps DL, Poindexter BB, Cotten CM, Van Meurs KP, Duara S, Narendran

Ohls, Page 21

V, Sood BG, O'Shea TM, Bell EF, Ehrenkranz RA, Watterberg KL, Higgins RD, Ohls RK (2010).Target ranges of oxygen saturation in extremely preterm infants. N Engl J Med, 362(21), 1959-69.

97. Finer NN, Carlo WA, Walsh MC, Rich W, Gantz MG, Laptook AR, Yoder BA, Faix RG, Das A,Poole WK, Donovan EF, Newman NS, Ambalavanan N, Frantz ID 3rd, Buchter S, Sanchez PJ,Kennedy KA, Laroia N, Poindexter BB, Cotten CM, Van Meurs KP, Duara S, Narendran V, SoodBG, O'Shea TM, Bell EF, Bhandari V, Watterberg KL, Higgins RD, Ohls RK (2010). Early CPAPversus surfactant in extremely preterm infants. N Engl J Med, 362(21), 1970-9.

98. Damaraju E, Phillips JR, Lowe JR, Ohls R, Calhoun VD, Caprihan A (2010). Resting-statefunctional connectivity differences in premature children.LID - 10.3389/fnsys.2010.00023 [doi]LID- 23 [pii]. Front Syst Neurosci, 4.

99. Bierer R, Roohi M, Peceny C, Ohls RK (2009). Erythropoietin increases reticulocyte counts andmaintains hematocrit in neonates requiring surgery. J Pediatr Surg, 44(8), 1540-5.

100. Maheshwari A, Kurundkar AR, Shaik SS, Kelly DR, Hartman Y, Zhang W, Dimmitt R, Saeed S,Randolph DA, Aprahamian C, Datta G, Ohls RK (2009). Epithelial cells in fetal intestine producechemerin to recruit macrophages. Am J Physiol Gastrointest Liver Physiol, 297(1), G1-G10.

101. Maheshwari A, Voitenok NN, Akalovich S, Shaik SS, Randolph DA, Sims B, Patel RP,Killingsworth CR, Fallon MB, Ohls RK (2009). Developmental changes in circulatingIL-8/CXCL8 isoforms in neonates. Cytokine, 46(1), 12-6.

102. Ohls RK (2009). Indications for Red Cell Transfusions in Preterm Infants. UpToDate.

103. Patel S, Rowe MJ, Winters SA, Ohls RK (2008). Elevated erythropoietin mRNA and proteinconcentrations in the developing human eye. Pediatr Res, 63(4), 394-7.

104. Ohls RK (2007). Transfusions in the Preterm Infant. Neoreviews, 8.

105. Ohls RK (2007). Indications for Red Cell Transfusions in Preterm Infants. UpToDate.

106. Warwood TL, Ohls RK, Lambert DK, Leve EA, Veng-Pedersen P, Christensen RD (2006). Urinaryexcretion of darbepoetin after intravenous vs subcutaneous administration to preterm neonates. JPerinatol, 26(10), 636-9.

107. Bierer R, Peceny MC, Hartenberger CH, Ohls RK (2006). Erythropoietin concentrations andneurodevelopmental outcome in preterm infants. Pediatrics, 118(3), e635-40.

108. Warwood TL, Ohls RK, Lambert DK, Jones C, Scoffield SH, Gupta N, Veng-Pedersen P,Christensen RD (2006). Intravenous administration of darbepoetin to NICU patients. J Perinatol, 26(5), 296-300.

109. Ohls RK, Dai A, Roohi M (2006). Darbepoetin Alfa: Pharmacokinetics and Clinical Use inNeonates. Haematol Rep, 2(10), 90-5.

110. Warwood TL, Ohls RK, Wiedmeier SE, Lambert DK, Jones C, Scoffield SH, Neeraj G,Veng-Pedersen P, Christensen RD (2005). Single-dose darbepoetin administration to anemicpreterm neonates. J Perinatol, 25(11), 725-30.

111. Ohls RK, Ehrenkranz RA, Das A, Dusick AM, Yolton K, Romano E, Delaney-Black V, Papile LA,Simon NP, Steichen JJ, Lee KG, National Institute of Child Health and Human DevelopmentNeonatal Research Network. (2004). Neurodevelopmental outcome and growth at 18 to 22 months'corrected age in extremely low birth weight infants treated with early erythropoietin and iron.Pediatrics, 114(5), 1287-91.

112. Ohls RK, Dai A (2004). Long-acting erythropoietin: clinical studies and potential uses in neonates.Clin Perinatol, 31(1), 77-89.

113. Ohls RK. (2002). Erythropoietin treatment in extremely low birth weight infants: blood in versusblood out. J Pediatr, 140, 3-6.

Ohls, Page 22

114. Ohls RK (2002). Erythropoietin and hypoxia inducible factor-1 expression in the mid-trimesterhuman fetus. Acta Paediatr Suppl, 91(438), 27-30.

115. Ohls RK (2002). Human recombinant erythropoietin in the prevention and treatment of anemia ofprematurity. Paediatr Drugs, 4(2), 111-21.

116. Ohls RK (2002). Changing transfusion practices in pediatrics. Transfus Altern Transfus Med, 4(3-4).

117. Ohls RK (2002). Management of anemia of prematurity using human recombinant erythropoietin.Transfus Altern Transfus Med, 4, 14-9.

118. Ohls RK, Ehrenkranz RA (2002). Reply to Letter to the Editor. Pediatrics, 110, 1254-5.

119. Ohls RK (2002). Reticulocyte hemoglobin content: an improved technique to measure ironsufficient erythropoiesis in preterm infants. Ital J Pediatr, 28, 337-8.

120. Ohls RK (2002). Anemia of the premature infant: a two year study of the response to ironmedication. J Pediatr, 41(1), 335.

121. Ohls RK, Bellis YM, Dupree JC, Sklar LC (2001). Effects of granulocyte colony-stimulating factoron neutrophil adhesive molecules in neonates. J Pediatr Hematol Oncol, 23(8), 506-10.

122. Ohls RK, Ehrenkranz RA, Wright LL, Lemons JA, Korones SB, Stoll BJ, Stark AR, Shankaran S,Donovan EF, Close NC, Das A (2001). Effects of early erythropoietin therapy on the transfusionrequirements of preterm infants below 1250 grams birth weight: a multicenter, randomized,controlled trial. Pediatrics, 108(4), 934-42.

123. Ohls RK, Ehrenkranz RA, Wright LL, Lemons JA, Korones SB, Stoll BJ, Stark AR, Shankaran S,Donovan EF, Close NC, Das A. (2001). Effects of early erythropoietin therapy on the transfusionrequirements of preterm infants below 1250 grams birthweight: a multi-center, randomizedcontrolled trial. Pediatrics, 108, 934-942.

124. Calhoun DA, Christensen RD, Edstrom CS, Juul SE, Ohls RK, Schibler KR, Sola MC, Sullivan SE(2000). Consistent approaches to procedures and practices in neonatal hematology. Clin Perinatol,27(3), 733-53.

125. Ohls RK (2000). The use of erythropoietin in neonates. Clin Perinatol, 27(3), 681-96.

126. Cogar AA, Hartenberger CH, Ohls RK (2000). Endothelin concentrations in preterm infants treatedwith human recombinant erythropoietin. Biol Neonate, 77(2), 105-8.

127. Ohls RK (1999). Erythropoietin to prevent and treat the anemia of prematurity. Curr Opin Pediatr,11(2), 108-14.

128. Ohls RK, Harcum J, Schibler KR, Christensen RD (1997). The effect of erythropoietin on thetransfusion requirements of preterm infants weighing 750 grams or less: a randomized,double-blind, placebo-controlled study. J Pediatr, 131(5), 661-5.

129. Ohls RK, Harcum J, Li Y, Davila G, Christensen RD (1997). Serum erythropoietin concentrationsfail to increase after significant phlebotomy losses in ill preterm infants. J Perinatol, 17(6), 465-7.

130. Ohls RK, Christensen RD (1996). Stability of human recombinant epoetin alfa in commonly usedneonatal intravenous solutions. Ann Pharmacother, 30(5), 466-8.

131. Ohls RK, Veerman MW, Christensen RD (1996). Pharmacokinetics and effectiveness ofrecombinant erythropoietin administered to preterm infants by continuous infusion in totalparenteral nutrition solution. J Pediatr, 128(4), 518-23.

132. Li Y, Ohls RK, Christensen RD (1996). Effects of recombinant granulocyte-macrophagecolony-stimulating factor on the capacity of mononuclear cells from preterm infants to generateinterleukin-6 and granulocyte colony-stimulating factor. Int J Pediat Hem Onc, 3, 63-7.

133. Li Y, Ohls RK, Christensen RD (1996). Effects of recombinant granulocyte-macrophage

Ohls, Page 23

colony-stimulating factor on the capacity of mononuclear cells from preterm infants to generateinterleukin-6 and granulocyte colony-stimulating factor. Int J Pediat Hem Onc, 3, 63-7.

134. Ohls RK, Christensen RD (1996). The pharmacologic stability of human recombinanterythropoietin in commonly used neonatal intravenous solutions. Ann Pharmacother, 30, 466-8.

135. Li Y, Ohls RK, Rosa C, Shah M, Richards DS, Christensen RD (1995). Maternal and umbilicalserum concentrations of granulocyte colony-stimulating factor and its messenger RNA duringclinical chorioamnionitis. Obstet Gynecol, 86(3), 428-32.

136. Ohls RK, Li Y, Abdel-Mageed A, Buchanan G Jr, Mandell L, Christensen RD (1995). Neutrophilpool sizes and granulocyte colony-stimulating factor production in human mid-trimester fetuses.Pediatr Res, 37(6), 806-11.

137. Ohls RK, Osborne KA, Christensen RD (1995). Efficacy and cost analysis of treating very lowbirth weight infants with erythropoietin during their first two weeks of life: a randomized,placebo-controlled trial. J Pediatr, 126(3), 421-6.

138. Ohls RK (1995). Recombinant human erythropoietin to prevent and treat the anemia ofprematurity. Erythropoiesis, 6, 35-45.

139. Schibler KR, Li Y, Ohls RK, Nye NC, Durham MC, White W, Liechty KW, Le T, Christensen RD(1994). Possible mechanisms accounting for the growth factor independence of hematopoieticprogenitors from umbilical cord blood. Blood, 84(11), 3679-84.

140. Schibler KR, Ohls RK, Le T, Liechty KW, Christensen RD (1994). Effect of recombinant stem cellfactor on clonogenic maturation and cycle status of human fetal hematopoietic progenitors. PediatrRes, 35(3), 303-6.

141. Christensen RD, Hunter DD, Ohls RK (1994). Pilot study comparing recombinant erythropoietinalone with erythropoietin plus recombinant granulocyte-macrophage colony-stimulating factor fortreatment of the anemia of prematurity. J Perinatol, 14(2), 110-3.

142. Ohls RK, Li Y, Trautman MS, Christensen RD (1994). Erythropoietin production by macrophagesfrom preterm infants: implications regarding the cause of the anemia of prematurity. Pediatr Res, 35(2), 169-70.

143. Ohls RK, Hunter DD, Christensen RD (1993). A randomized, double-blind, placebo-controlled trialof recombinant erythropoietin in treatment of the anemia of bronchopulmonary dysplasia. J Pediatr,123(6), 996-1000.

144. Brown MS, Jones MA, Ohls RK, Christensen RD (1993). Single-dose pharmacokinetics ofrecombinant human erythropoietin in preterm infants after intravenous and subcutaneousadministration. J Pediatr, 122(4), 655-7.

145. Liechty KW, Schibler KR, Ohls RK, Perkins SL, Christensen RD (1993). The failure of newbornmice infected with Escherichia coli to accelerate neutrophil production correlates with their failureto increase transcripts for granulocyte colony-stimulating factor and interleukin-6. Biol Neonate, 64(5), 331-40.

146. Ohls RK, Christensen RD (1993). Reply to Letter to the Editor. Pediatrics, 91.

147. Ohls RK, Christensen RD (1991). Recombinant erythropoietin compared with erythrocytetransfusion in the treatment of anemia of prematurity. J Pediatr, 119(5), 781-8.

148. Christensen RD, Liechty KW, Koenig JM, Schibler KR, Ohls RK (1991). Administration oferythropoietin to newborn rats results in diminished neutrophil production. Blood, 78(5), 1241-6.

149. Holbrook ST, Ohls RK, Schibler KR, Yang YC, Christensen RD (1991). Effect of interleukin-9 onclonogenic maturation and cell-cycle status of fetal and adult hematopoietic progenitors. Blood, 77(10), 2129-34.

150. 84. Ohls RK, Wirkus PE, Christensen RD (1991). Recombinant erythropoietin as treatment for theOhls, Page 24

late hyporegenerative anemia of Rh hemolytic disease. J Pediatr, 119, 781-8.151. Ohls RK, Liechty KW, Turner MC, Kimura R, Christensen RD (1990). Erythroid "burst

promoting" activity in serum of patients with the anemia of prematurity. J Pediatr, 116(5), 786-9.152. Ohls RK, Osborn LM (1988). Maternal depression: the pediatrician's role. Contemp Peds, 5,

103-12.

REVIEW ARTICLES1. Maxwell JR, Yellowhair TR, Oppong AY, Camacho JE, Lowe JR, Jantzie LL, Ohls RK (2017).

Cognitive development in preterm infants: multifaceted deficits reflect vulnerability of rigorousneurodevelopmental pathways. [Review]. Minerva Pediatr, 69, (4), 298-313.

2. Bishara N, Ohls RK (2009). Current controversies in the management of the anemia of prematurity.[Review]. Semin Perinatol, 33, (1), 29-34.

BOOK CHAPTERS1. Maxwell JM, Ohls RK (2019). Update on Erythropoiesis Stimulating Agents Administered to

Neonates for Neuroprotection.. In NeoReviews (20, p. 11).2. DuPont TL, Ohls RK (2018). Placental Transfusion: Current Practices and Future Directions. In

NeoReviews (19).3. Ohls RK (2018). Transfusion Thresholds in the Neonatal Intensive Care Unit. In Ohls RK,

Maheshwari A, Christensen RD (Eds.), Questions and Controversies in Neonatology Series:Hematology, Immunology, and Genetics (3rd Edition). Philadelphia: Elsevier Health Science.

4. Christensen RD, Ohls RK (2018). Anemias Unique to the Neonatal Period. In Greer JP, Foerster J,Lukens JN, Rodgers GM, Paraskevas F, Glader B, Mead T (Eds.), Wintrobe’s Clinical Hematology(14th Edition). Philadelphia: Lippincott Williams and Wilkins.

5. Ohls RK (2015). Anemia. In Polin R, Yoder MC (Eds.), Workbook in Practical Neonatology (5thEdition). WB Saunders Company.

6. Ohls RK, Bishara N, Wong W, Glader B (2015). Anemia in the Neonatal Period. In Stevenson DK,Van Meurs K (Eds.), Neonatology: Clinical Practice and Procedures New York City: McGraw-HillCompanies.

7. Christensen RD, Ohls RK (2013). Anemias Unique to the Fetus and Neonate. In Greer JP, FoersterJ, Lukens JN, Rodgers GM, Paraskevas F, Glader B, Mead T (Eds.), Wintrobe’s ClinicalHematology (13th Edition). Philadelphia: Lippincott Williams and Wilkins.

8. Ohls RK, Christensen RD (2013). Development of the Hematopoietic System. In Kliegman RM,Stanton BF, St Geme JW, Schor NF, Behrman RE (Eds.), Nelson Textbook of Pediatrics (20thEdition). WB Saunders Company.

9. Ohls RK (2012). Why, When and How Should We Provide Red Cell Transfusions andErythropoiesis Stimulating Agents to Support Red Cell Mass In Neonates. In Ohls RK, MaheshwariA (Eds.), Questions and Controversies in Neonatology Series: Hematology, Immunology, andInfectious Diseases (2nd Edition). Philadelphia: Elsevier Health Science.

10. Ohls RK (2011). Developmental Erythropoiesis. In Polin RA, Fox WW, Abman S (Eds.), Fetal andNeonatal Physiology (4th Edition). Philadelphia: WB Saunders Company.

11. Ohls RK, Christensen RD (2011). Developmental Hematopoiesis. In Kliegman RM, Stanton BF, StGeme JW, Schor NF, Behrman RE (Eds.), Nelson Textbook of Pediatrics (19th Edition).Philadelphia: WB Saunders Company.

Ohls, Page 25

12. Christensen RD, Ohls RK (2008). Anemias Unique to the Newborn Period. In Greer JP, Foerster J,Lukens JN, Rodgers GM, Paraskevas F, Glader B, Mead T (Eds.), Wintrobe’s Clinical Hematology(12th Edition). Philadelphia: Lippincott Williams and Wilkins.

13. Ohls RK, Christensen RD (2007). Development of the Hematopoietic System. In Behrman RE,Kliegman R, Arvin AM (Eds.), Nelson Textbook of Pediatrics (18th Edition). Philadelphia: WBSaunders Company.

14. Ohls RK (2007). Anemia in the Newborn Infant. In Polin R, Yoder MC (Eds.), Workbook inPractical Neonatology (4th Edition). WB Saunders Company.

15. Ohls RK (2007). Red cell transfusions in neonates. In Ohls RK, Yoder M (Eds.), Questions andControversies in Neonatology Series: Hematology, Immunology, and Infectious DiseasesPhiladelphia: Elsevier Health Science.

16. Ohls RK, Christensen RD (2005). Development of the Hematopoietic System. In Behrman RE,Kliegman R, Arvin AM (Eds.), Nelson Textbook of Pediatrics (17th Edition). Philadelphia: WBSaunders Company.

17. Christensen RD, Ohls RK (2004). Anemias Unique to Pregnancy and the Neonatal Period. In GreerJP, Foerster J, Lukens JN, Rodgers GM, Paraskevas F, Glader B (Eds.), Wintrobe’s ClinicalHematology (11th Edition). Philadelphia: Lippincott Williams and Wilkins.

18. Ohls RK (2004). Anemia in the Neonatal Period. In Osborn LM, DeWitt TG, First LR (Eds.),Comprehensive Pediatrics (1st Edition). Philadelphia: Elsevier Health Science.

19. Ohls RK (2003). Developmental Erythropoiesis. In Polin RA, Fox WW (Eds.), Fetal and NeonatalPhysiology (3rd Edition). Philadelphia: WB Saunders Company.

20. Ohls RK (2001). Hematology. In Polin RA, Spitzer AR (Eds.), Fetal and Neonatal SecretsPhiladelphia: Hanley and Belfus, Inc.

21. Ohls RK (2000). Anemia in the Newborn Period. In Polin R, Yoder MC (Eds.), Workbook inPractical Neonatology (3rd Edition). WB Saunders Company.

22. Ohls RK (2000). Evaluation and Treatment of Anemia in the Neonate. In Christensen RD (Ed.),Hematologic Problems of the Neonate Philadelphia: WB Saunders Company.

23. Ohls RK, Christensen RD (1999). Developmental Hematopoiesis. In Behrman RE, Kliegman R,Arvin AM (Eds.), Nelson Textbook of Pediatrics (16th Edition). Philadelphia: WB SaundersCompany.

24. Ohls RK (1997). Developmental Erythropoiesis. In Polin RA, Fox WW (Eds.), Fetal and NeonatalPhysiology (2nd Edition). Philadelphia: WB Saunders Company.

25. Ohls RK (1996). Development of the Fetal Immune System. In Bronson RA, Alexander NJ,Anderson DJ, Branch DW, Kutteh WH (Eds.), Reproductive Immunology Blackwell ScientificPublishers.

26. Ohls RK, Christensen RD (1995). Developmental Hematopoiesis. In Behrman RE, Kliegman R,Arvin AM (Eds.), Nelson Textbook of Pediatrics (15th Edition). Philadelphia: WB SaundersCompany.

ADDITIONAL PUBLICATIONSCase Reports1. Ohls RK, Wirkus PE, Christensen RD (1992). Recombinant erythropoietin as treatment for the late

hyporegenerative anemia of Rh hemolytic disease. Pediatrics, 90(5), 678-80.

Editorials

Ohls, Page 26

1. Ohls RK, Christensen RD, Widness JA, Juul SE (2015). Erythropoiesis Stimulating AgentsDemonstrate Safety and Show Promise as Neuroprotective Agents in Neonates. 167(1), 10-2.

2. Ohls RK (2002). Erythropoietin treatment in extremely low birth weight infants: blood in versusblood out. J Pediatr, 141(1), 3-6.

Others1. Ohls RK (December 2010). Erythropoietin as Treatment for Neonatal Hypoxic Ischemic

Encephalopathy. Foundation for Women and Infant Health News Bulletin

Multimedia1. Ohls RK (2015). How to obtain blood from a placenta [Web], YouTube. Available:

https://youtu.be/_N7OuhgmxPI.2. Ohls RK (2007). Expert Commentary [Web], Society for the Advancement of Blood Management.

Available: http://www.sabm.org/professionals/reference/detail.php?newsid=368.

PENDING PUBLICATIONSJournal Articles1. Charlton JR, Boohaker L, Askenazi D, Brophy P, D’Angio C, Fuloria M, Gien J, Grifin R,

Hingorani S, Ingraham S, Mian A, Ohls RK, Rastogi S, Rhee CJ, Revenis M, Sarkar A, Smith A,Starr M, Kent AL (In Press). Risk Factors of Early Onset Neonatal Acute Kidney Injury: Resultsfrom the AWAKEN Study (Assessment of Worldwide Acute Kidney Injury Epidemiology inNeonates). Clin J Am Soc Nephrol.

RECENTLY PUBLISHED ABSTRACTS (LAST 3 YEARS)1. Ohls RK (2020). Improved neurodevelopmental outcomes with increased iron dose in extremely

low gestational age neonates (ELGANs) in the Preterm Erythropoietin Neuroprotection Trial(PENUT). PAS 2020 [Abstract]. E-Pediatric Academic Society, .

2. Ohls RK (2020). Darbepoetin as a Neuroprotective Agent in Mild Neonatal Encephalopathy(MEND): A Randomized, Placebo Controlled, Masked, Feasibility Trial. PAS 2020 [Abstract].E-Pediatric Academic Society, .

3. Ohls RK (2020). A randomized trial of higher versus lower hemoglobin transfusion thresholds forextremely low birth weight (ELBW) infants: The Transfusion of Prematures (TOP) Trial. PAS 2020[Abstract]. E-Pediatric Academic Society, .

4. U Nwokidu-Aderibigbe, L Jantzie, J Maxwell, S Beauman and RK Ohls (2020). Stability ofdarbepoetin in neonatal intravenous fluids. PAS 2020 [Abstract]. E-Pediatric Academic Society, .

5. Ohls RK (2020). Warming blood products for transfusion to neonates: in vitro assessments. PAS2020 [Abstract]. E-Pediatric Academic Society, .

6. Ohls RK (2020). Erythropoietin (Epo) and neurodevelopment in iron-sufficient extremely lowgestational age neonates (ELGANs); a secondary analysis of the Preterm ErythropoietinNeuroprotection Trial (PENUT) .PAS 2020 [Abstract]. E-Pediatric Academic Society, .

7. Ohls RK (2020). A Randomized Trial of Laparotomy versus Peritoneal Drainage in Extremely LowBirth Weight Infants with Necrotizing Enterocolitis or Isolated Intestinal Perforation: Outcomesthrough 18-22 Months Corrected Age. PAS 2020 [Abstract]. E-Pediatric Academic Society, .

8. NWokido-Aderabigbe U, Ohls RK (2020). Darbe in IV fluids [Presented at WSPR, Carmel, CA] [Abstract]. WSPR, .

Ohls, Page 27

9. U Nwokidu-Aderibigbe, L Jantzie, J Maxwell, S Beauman and RK Ohls (2020). Stability ofdarbepoetin in neonatal intravenous fluids. J Invest Med 2020;68:465. [Abstract]. J Invest Med, 68,465.

10. Juul SE, Comstock B, Mayock D, Heagerty P, Study Group PENUT Investigators (2019).Erythropoietin prophylaxis for neuroprotection of extremely low gestational age neonates: thePENUT trial two year outcomes. E-PAS [Abstract]. E-Pediatric Academic Society, 2175, 3.

11. Ahmad KA, Bennett MM, Juul SE, Ohls RK, Clark RH, Tolia V (2019). Utilization oferythropoietin in the United States Neonatal Intensive Care Units from 2008-2017. E-PAS[Abstract]. E-Pediatric Academic Society, 1853, 414.

12. Mayock D, Comstock B, Heagerty P, Juul SE, Study Group PENUT Investigators (2019). Therelationship between retinopathy of prematurity and erythropoietin in extremely low gestational ageneonates. E-PAS [Abstract]. E-Pediatric Academic Society, 2175, 4.

13. Mayock D, Comstock B, Heagerty P, Juul SE, Study Group PENUT Investigators (2019). Shortterm safety of high dose neonatal erythropoietin administered prophylactically to extremely lowgestational age neonates in the PENUT trial. E-PAS [Abstract]. E-Pediatric Academic Society, 4171, 646.

14. Kiser R, Leung R, Yaroslaski AM, Zamora TA, Ohls RK (2019). Reticulocyte hemoglobincompared to ferritin as a biomarker of iron status in preterm infants receiving erythropoietin. E-PAS[Abstract]. E-Pediatric Academic Society, 1853, 413.

15. S Cooper, C Batty, J Lowe, S Rossol, R Rieger and RK Ohls (2019). Impact of erythropoiesisstimulating agents on behavioral measures in school age children born preterm. J Invest Med2019;67:367. [Abstract]. J Invest Med, 67, 367.

16. R Kiser, A Yaroslaski, R Leung, RK Ohls and T Zamora (2019). Reticulocyte hemoglobin andferritin as markers of iron deficency in the neonate. J Invest Med 2019;67:120

[Abstract]. J Invest Med, 67, 120.17. Lowe JR, Rieger R, Moss N, Rossol S, Yeo R, Ohls RK (2018). Impact of erythropoiesis

stimulating agents in behavioral measures in school age children born preterm [oral presentationalso given at the 2018 Pediatric Academic Societies Meeting, Toronto, Ontario, Canada] [Abstract].E-Pediatric Academic Societies, .

18. Milner C, Ohls RK, Cannon DC, Phillips J, Lowe JR (2018). Parental assessment correlates withtests of executive function at school age in former preterm infants administered ESAs [posterpresentation also given at the 2018 Pediatric Academic Societies Meeting, Toronto, Ontario,Canada] [Abstract]. E-Pediatric Academic Societies, .

POSTER PRESENTATIONS2015 Moss N, Ohls RK, Lowe J. The Relationship Between Primary Language,

Socioeconomic Status, and Executive Function in Preschoolers Born Very LowBirth Weight. Poster session presented at Society of Pediatric Psychology AnnualConference, San Diego, CA.

2015 Reiger R, Ohls RK, Lowe J. Maternal and Child Affect, Medical Risk, andDevelopmental Outcomes in Very Low Birth Weight Preschoolers. Poster sessionpresented at Society of Pediatric Psychology Annual Conference, San Diego, CA.

2015 Möbius MA, Koß S, Freud D, Ohls RK, Rüdiger M, Thébaud B. Mesenchymalstem- or stromal cells from the developing human lung are perturbed by hyperoxia.Poster session presented at CUROSURF Meeting, Stockholm, Sweden.

Ohls, Page 28

2014 Cannon DC, Mani S, Hartenberger C, Peceny H, Ballard K, Ohls RK. Focusedproteomic profiling for rapid detection of late-onset neonatal sepsis in preterminfants. Poster session presented at American Medical Informatics AssociationAnnual Symposium, Washington, DC.

2014 Moss N, Lowe J, Ohls RK. Associations between Maternal Scaffolding andExecutive Functioning in 3 and 4 Year Olds Born Very Low Birth Weight andNormal Birth Weight. Poster session presented at Society of Pediatric PsychologyAnnual Conference, Philadelphia, PA.

2014 Reiger R, Moss N, Duvall S, MacLean P, Ohls RK, Lowe J, Erickson SJ. GenderDifferences in Maternal Verbal Scaffolding, Verbal IQ, and Executive FunctioningAmong Preschoolers Born Preterm. Poster session presented at Society of PediatricPsychology Annual Conference, Philadelphia, PA.

2013 Mani S, Cannon D, Hartenberger C, Ballard K, Peceny H, Ohls RK. FocusedProteomic Profiling for Late Onset Neonatal Sepsis. Poster session presented atAmerican Medical Informatics Association Annual Symposium, Washington, DC.

2009 Caprihan A, Sakoglu U, Pfeuffer J, Rael J, Stephen J, Lowe J, Duvall S,Gasparovic C, Ohls RK, Phillips JP. Differences in Blood Perfusion betweenExtremely Low Birth Weight (ELBW) Pre-term Infants and Control Term Infants.Poster session presented at International Society of Magnetic Resonance inMedicine 17th Scientific Meeting & Exhibition, Honolulu, HI.

2007 Ma I, Rowe MJ, Patel S, Padilla M, Ohls RK. Erythropoietin and vascularendothelial growth factor mRNA and protein expression in the developing humaneye. Poster session presented at Department of Pediatrics Research Day, Universityof New Mexico School of Medicine, Albuquerque, NM.

2006 Patel S, Rowe M, Ohls RK. Erythropoietin protein expression in the developinghuman eye. Poster session presented at American Academy of Pediatrics - DistrictVIII Perinatal Conference, Girdwood, AK.

1994 Christensen RD, Schibler KR, Li Y, Ohls RK. Granulopoiesis in the mid-trimesterhuman fetus: production and actions of granulocyte colony stimulating factor.Poster session presented at Southern Society for Pediatric Research, HematologySession, New Orleans, LA.

ORAL PRESENTATIONSKeynote/Plenary LecturesNational2014 Ohls RK. Erythropoiesis Stimulating Agents in the NICU: Has their time come?

Western Perinatal Fellows Conference, Indian Wells, CA1999 Ohls RK, Ehrenkranz RA, Lemons JA, Korones SB, Stoll BJ, Stark AR, Wright

LL, Shankaran S, Donovan EF, Zimmerman N, for the NICHD Neonatal ResearchNetwork. A multi-centered, randomized, double-blind, placebo-controlled trial oferythropoietin administration to premature infants ≤1250 grams birth weight.American Federation for Medical Research 1999 Western Regional Meeting,Plenary Session, Carmel, CA

1993 Schibler KS, Nye NC, Durham MC, White WL, Liechty KW, Ohls RK,Christensen RD. Unique features of human fetal hematopoietic progenitor cellgrowth in vitro. American Federation for Medical Research 1993 WesternRegional Meeting, Plenary Session, Carmel, CA

Ohls, Page 29

1992 Liechty KW, Schibler KR, Ohls RK, Christensen RD. Defective regulation oftranscripts for granulocytopoietic cytokines in newborn mice inoculated withEscherichia coli. American Federation for Medical Research 1992 WesternRegional Meeting, WSCI/WSAFCR Combined Plenary Session, Carmel, CA

1991 Ohls RK, Christensen RD. A randomized trial of erythropoietin administrationversus erythrocyte transfusion in patients with the anemia of prematurity.American Federation for Medical Research 1991 Western Regional Meeting,Plenary Session, Carmel, CA

Meeting PresentationsInternational2013 Ohls RK, Christensen RD, Wiedmeier S, Kamath-Rayne B, Rosenberg A,

Schrader R, Backstrom Lacy C, Lambert D, Burnett J, Pruckler B, Peceny H,Schrader R, Lowe JR. Neurocognitive outcomes in former preterm infantsadministered Darbepoetin or Erythropoietin. International Congress of Pediatrics,Melbourne, Australia

2009 Caprihan A, Sakoglu U, Pfeuffer J, Rael J, Duvall SW, MacLean PC, Silva LM,Gasparovic C, Lowe J, Ohls RK, Phillips JP. Cerebral Blood Perfusion andDevelopment in Former Premature and Control Infants. American Academy forCerebral Palsy and Developmental Medicine Conference, Scottsdale, AZ

2009 Woolsey Duvall S, Mclean PC, Silva LM, Ohls R, Phillips J. Magnetic ResonanceSpectroscopy Predicts Performance IQ in Low-Birthweight Children. AmericanAcademy for Cerebral Palsy and Developmental Medicine Conference, Scottsdale,AZ

2009 Il Kim D, Caprihan A, Ruhl D, Woolsey Duvall S, Silva LM, Mclean PC, LoweJR, Ohls RK, Phillips J. Does Prematurity Effect Functional Connectivity In TheDeveloping Brain? A Resting Functional Magnetic Resonance Imaging Study.American Academy for Cerebral Palsy and Developmental Medicine Conference,Scottsdale, AZ

2009 Duvall SW, Silva LM, Maclean PC, Lowe JR, Caprihan A, Ohls RK, GasparovicC, Ruhl D, Phillips JP. Brain Structure And Development In Children BornPreterm And Full-Term. American Academy for Cerebral Palsy andDevelopmental Medicine Conference, Scottsdale, AZ

2009 Mclean PC, Woolsey Duvall SW, Ruhl D, Gasparovic C, Caprihan A, Silva LM,Ohls R, Phillip J, Lowe JR. Neuroanatomic Deficits Associated With PrematurityNormalize In Early Childhood. American Academy for Cerebral Palsy andDevelopmental Medicine Conference, Scottsdale, AZ

1985 Adair JC, Ohls RK, Schultz DE. Effects of physician specialty training on attitudestowards cardiac rehabilitation. North American Primary Care Research Group 13thAnnual Meeting, Seattle, WA

National2007 Patel, S, Ma I, Rowe MJ, Padilla M, Ohls RK. Erythropoietin and vascular

endothelial growth factor mRNA and protein expression in the developing humaneye. American Academy of Pediatrics - District VIII Annual Meeting, Bernalillo,NM

Ohls, Page 30

2006 Ohls RK, Padilla M, Dai A, Palmisano W. Developmental regulation oferythropoietin gene expression through methylation. American Academy ofPediatrics - District VIII Perinatal Conference, Girdwood, AK

2005 Snyder SA, Ohls RK, Alverson DC, Lyons CR, Helman P, Veroff R.Inflammatory mediators as predictors of neonatal sepsis and recovery. AmericanAcademy of Pediatrics - District VIII Perinatal Conference, Midway, UT

2005 Warwood TL, Ohls RK, Weidmeier SE, Lambert DK, Jones C, Scoffield SH,Neeraj G, Veng-Pederson P, Christensen RD. Single-dose Darbepoetinadministrations to anemic preterm neonates. American Academy of Pediatrics -District VIII Perinatal Conference, Midway, UT

Local/Regional2020 Erythropoiesis stimulating agents in term and preterm neonates Research in

Progress University of Utah, Salt Lake City, UT2020 Translational research in human development: molecular transitions from womb to

extremely preterm birth Scholarly Activity Monthly, University of Utah, Salt LakeCity, UT

1994 Ohls RK, Christensen RD. A randomized, placebo-controlled trial oferythropoietin administration on the transfusion requirements of very low birthweight infants in the first two weeks of life. Southern Society for PediatricResearch, Neonatology Session, New Orleans, LA

1994 Li Y, Ohls RK, Christensen RD. Erythropoietin receptor expression in neonataland adult macrophages. Southern Society for Pediatric Research, HematologySession, New Orleans, LA

Invited/Visiting Professor Presentations

International2017 Ohls RK. Protecting the newborn brain – can erythropoiesis stimulating agents

improve neurodevelopmental outcome? Presidential Lecture: American Academyfor Cerebral Palsy and Developmental Medicine Annual Meeting, Montreal,Quebec, Canada

2015 Ohls RK. Darbepoetin in Term and Preterm Neonates. Heme Conference,Palermo, Sicily, Italy

2013 Ohls RK. Transfusions in Newborns. Acapulco, Mexico2013 Ohls RK. Use of Erythropoiesis Stimulating Agents in the Newborn. Acapulco,

Mexico2013 Ohls RK. Erythropoiesis Stimulating Agents to Support Red Cell Mass in

Neonates. AABB Meeting, Denver, CO2010 Ohls RK. Erythropoiesis Stimulating Agents versus Red Cell Transfusions to

Support Red Cell Mass in the Preterm Infant. Pediatric Academic Societies AnnualMeeting, Vancouver, British Columbia, Canada

2008 Ohls RK. Red Cell Growth Factors. Keystone FRAN Symposia, Keystone, CO2008 Ohls RK. Transfusion Guidelines. Keystone FRAN Symposia, Keystone, CO2007 Ohls RK. Transfusions and Red Cell Growth Factors in Neonates. American

Academy of Pediatrics - District VIII Annual Meeting, Bernalillo, NM

Ohls, Page 31

2006 Ohls RK. Transfusion Practices and Erythropoietin Administration in Neonates.Grand Rounds, Port of Spain General Hospital, Port of Spain, Trinidad and Tobago

2006 Ohls RK. Clinical Indications and Guidelines For Use of Transfusion Alternativesin Neonates. Grand Rounds, Petrotrin Hospital, San Fernando, Trinidad andTobago

2006 Ohls RK. Transfusion Practices and Erythropoietin Administration in Neonates.Grand Rounds, San Fernando Hospital, San Fernando, Trinidad and Tobago

2006 Ohls RK. Evaluation and Treatment of Anemia in Neonates. Grand Rounds, EricWilliams Pediatric Hospital, Port of Spain, Trinidad and Tobago

2006 Ohls RK. Transfusion Practices and Erythropoietin Administration in Neonates.Grand Rounds, Mount Hope Hospital, Port of Spain, Trinidad and Tobago

2006 Ohls RK. Darbepoetin Pharmacokinetics and Clinical Use in Neonates. FourthInternational Developmental Hematology Conference, Brescia, Italy

2006 Ohls RK. Transfusions in Neonates: Too Much of a Good Thing, or Not Enough?Hot Topics in Neonatology, Pediatric Academic Societies Meeting, San Francisco,CA

2005 Ohls RK. New Long Acting Erythropoietin: Clinical Studies in Adults, Childrenand Neonates. American Academy of Pediatrics - District VIII PerinatalConference, Midway, UT

2005 Ohls RK. Transfusion Strategies and Blood Conservation in Neonates. GrandRounds, Schneider Children’s Hospital/ Long Island Jewish Medical Center(broadcast to Tel Aviv, Israel), New York, NY

2004 Ohls RK. Transfusion Practices and Erythropoietin Administration in Neonates.Grand Rounds, Manipal Medical College, Malaka, Malaysia

2004 Ohls RK. The Use of Erythropoietin in Neonates. Grand Rounds, University ofMalaya, Kuala Lumpur, Malaysia

2004 Ohls RK. Transfusions and Erythropoietin in Neonates. Grand Rounds, HospitalPutrajaya, Putrajaya, Malaysia

2004 Ohls RK. Neonatal Blood Conservation: A Review of Current Strategies. GrandRounds, Selayang Hospital, Selangor, Malaysia

2004 Ohls RK. Neonatal Blood Conservation: A Review of Current Strategies. GrandRounds, Kuala Lumpur General Hospital, Kuala Lumpur, Malaysia

2004 Ohls RK. Neonatal Blood Conservation: A Review of Current Strategies. Societyfor Advancement of Blood Management Symposium, Bal Harbour, FL

2002 Ohls RK. Erythropoietin Kinetics in the Fetus and Preterm Infant. InternationalConference on Neonatal Hematology and Immunology, Session on Erythropoietin,Orlando, FL

2000 Ohls RK. The Use of Erythropoietin in Neonates. American Association of BloodBanks Annual Meeting, Washington, DC

2000 Ohls RK. 2nd Iberian American Bloodless Medicine and Surgery Congress,Mexico City, Mexico

1991 Ohls RK. Erythropoietin as an alternative to transfusions for neonatal anemias.American Association of Blood Banks Annual Meeting, Baltimore, MD

National

Ohls, Page 32

2019 Red Cell Transfusion Guidelines and Developmental Outcomes in PretermInfants. Miami Neonatology Conference, Miami, FL

2019 Erythropoiesis Stimulating Agents: Outcomes in Preterm Neonates. MiamiNeonatology Conference, Miami, FL

2019 Are Erythropoiesis Stimulating Agents Neuroprotective in Neonates? AustinMEDNAX NEO Conference, Austin TX

2019 Erythropoiesis Stimulating Agents in the NICU. MEDNAX NEO Conference,Orlando FL

2018 Use of Erythropoiesis Stimulating Agents to Increase Red Cell Mass andImprove Neurodevelopmental Outcome in Preterm Infants. District VI AnnualMeeting, Chicago, IL

2018 Ohls RK. Darbepoetin in the NICU. American Academy of Pediatrics - DistrictVIII Annual Meeting, Midway, UT

2018 Ohls RK. Cool Topics: Neuroprotective Effects of Erythropoiesis StimulatingAgents in Preterm Infants. California Association of Neonatologists Meeting,Coronado, CA

2018 Ohls RK. Use of Erythropoiesis Stimulating Agents to Increase Red Cell Mass andImprove Neurodevelopmental Outcome in Preterm Infants. American Academy ofPediatrics - District VI Annual Meeting, Chicago, IL

2017 Ohls RK. Protecting the newborn brain – can erythropoiesis stimulating agentsimprove neurodevelopmental outcome? Cincinnati Children’s Hospital MedicalCenter Grand Rounds, Cincinnati, OH

2017 Ohls RK. University of Colorado Fred Battaglia State-of-the-Art Speaker:Protecting the newborn brain – can erythropoiesis stimulating agents improveneurodevelopmental outcome? Western Medical Research Conference,Developmental Biology Session, Carmel, CA

2016 Ohls RK. Debbie Matthei Memorial Lecture: Strategies to Improve Red Cell Massin Neonates. Augusta University Neonatology Conference, Augusta, GA

2016 Ohls RK. Erythropoiesis Stimulating Agents in the NICU. Guest Professor,University of California, Irvine Fellows Conference, Irvine, CA

2016 Ohls RK. Protecting the newborn brain – Can Darbepoetin improveneurodevelopmental outcome? California Association of Neonatologists Meeting,Coronado, CA

2016 Ohls RK. Transfusions in Neonates: Strategies to Improve Red Cell Mass. NEOConference, Orlando, FL

2014 Ohls RK. Transfusions. Maui, HI2014 Ohls RK. Anemia in Neonates. Maui, HI2014 Ohls RK. Red Cell Growth Factors. Maui, HI2013 Ohls RK. When to Transfuse Preterm Infants. Charlotte, NC2013 Ohls RK. Red Cell Transfusion Guidelines in Extremely Low Birth Weight

Infants. Charlotte, NC2013 Ohls RK. Neonatal Blood Management and Transfusion Guidelines. Webinar2012 Ohls RK. Neonatal Anemia and Transfusions. NeoPREP Conference, New

Orleans, LA

Ohls, Page 33

2010 Ohls RK. Technology, Research and ? Still Looking for that Missing Piece.Neonatal Grand Rounds, University of British Columbia, Vancouver, BritishColumbia, Canada

2008 Ohls RK. Changing Transfusion Guidelines in Neonatology. University of IowaInvited Neonatologist Day, Iowa City, IA

2008 Ohls RK. Hematopoietic and Non-hematopoietic Impact of Red Cell GrowthFactors in Neonates. Neonatal Grand Rounds, Anchorage, AK

2008 Ohls RK. Changing Transfusion Practices in Adult, Pediatric and Neonatal CriticalCare Patients. Neonatal Grand Rounds, Anchorage, AK

2008 Ohls RK. Evaluation of a Low Hematocrit in the Neonatal Period. Neonatal GrandRounds, Anchorage, AK

2008 Ohls RK. Evaluation of Anemia in Neonates. Pediatric Grand Rounds, Anchorage,AK

2008 Ohls RK. Erythropoiesis and Erythropoiesis Stimulating Agents. Grand Rounds,University of Colorado School of Medicine, Denver, CO

2008 Ohls RK. The Use of Erythropoiesis Stimulating Agents in Neonates. Universityof Iowa, Iowa City, IA

2008 Ohls RK. Update on Neonatal Transfusion Guidelines. Pediatrix Annual Meeting,Chicago, IL

2008 Ohls RK. What Should the Hematocrit Be Now? Dialogs in Neonatal PerinatalMedicine, Duke University, Durham, NC

2008 Ohls RK. Optimal Hematocrit for the Non-growing Preterm Infant. Dialogs inNeonatal Perinatal Medicine, Duke University, Durham, NC

2007 Ohls RK. Transfusions and Red Cell Growth Factors in Neonates. Red Hot ChiliTopics, Southern Society For Pediatric Research/District VII Annual Meeting,New Orleans, LA

2006 Ohls RK. Long Acting Erythropoietin: Clinical Studies in Adults, Children andNeonates. University of Florida Visiting Professorship, Gainesville, FL

2006 Ohls RK. Transfusion Guidelines in Neonates. University of Florida VisitingProfessorship, Gainesville, FL

2004 Ohls RK. Long acting Erythropoietin: Clinical Studies and Potential Uses inNeonates. Hematopoietic Growth Factors and Specific Antibacterial AntibodyPreparations in Neonatology, University of South Florida, Orlando, FL

2004 Ohls RK. Early- and Late-Onset Infection in Neonates: Current Indicators andFuture Prospects. Hematopoietic Growth Factors and Specific AntibacterialAntibody Preparations in Neonatology, University of South Florida, Orlando, FL

2004 Ohls RK. Changing Transfusion Practices in Neonates. Blood ConservationConference: Strategies in Adult and Pediatric Care, Philadelphia, PA

2004 Ohls RK. Transfusions and Erythropoietin in Neonates: Current and FutureConsiderations. Pediatric Blood Conservation Conference, Grand Rapids, MI

2003 Ohls RK. Diagnosing Anemia in the Neonate. Hematology Updates, Albuquerque,NM

2002 Ohls RK. Hemorrhagic, Hemolytic, and Hypoproliferative Anemia in the Neonate.Hematology Update, Albuquerque, NM

Ohls, Page 34

2002 Ohls RK. Erythropoietin in Neonates. It Really Works. Really. NeonatalPharmacology Conference, San Francisco, CA

2002 Ohls RK. Mechanisms of Inflammation and Treatment of Infection withNon-Antimicrobial Agents: What are Our Options? Neonatal PharmacologyConference, San Francisco, CA

2002 Ohls RK. State of the Art Presentation: The Effects of Preterm Birth onDevelopmental Erythropoiesis. Western Society for Pediatric Research,Developmental Biology Session, Carmel, CA

2001 Ohls RK. Humor in the Neonatal Setting: What Were You Thinking?!?!? NationalAssociation of Neonatal Nurses Conference, Albuquerque, NM

2001 Ohls RK. The Use of Erythropoietin in Neonates. Grand Rounds, Washoe MedicalCenter, Reno, NV

1999 Ohls RK. The Transition Period. Current Concepts and Controversies,Albuquerque, NM

1998 Ohls RK. Erythropoietin as an Alternative to Transfusions in Preterm Infants.Fourth National Seminar, National Bloodless Medicine and Surgery Association:Exploring New Frontiers in Medicine, Chicago, IL

1998 Ohls RK. Alternatives to transfusions in neonates. 76th Annual Meeting, TexasPerinatal Society, American Academy of Pediatrics, Corpus Christi, TX

1998 Ohls RK. Inclusion of children in research. Issues in Human Research: A Focus onSouthwestern Diversity, Albuquerque, NM

1997 Ohls RK. Erythropoietin as an alternative to transfusions in neonates. BloodlessMedicine and Surgery Conference, Boston, MA

1997 Ohls RK. G-CSF and neonatal sepsis. Signal Transduction and Cell AdhesionConference, Albuquerque, NM

1997 Ohls RK. The effects of granulocyte colony stimulating factor on PMN adhesionin neonates with sepsis. Amgen Granulocyte-Colony Stimulating Factor (G-CSF)Research Conference, Marina Del Rey, CA

1996 Ohls RK. Neonatal Hematology. National Association of Neonatal NursesConference, Albuquerque, NM

1996 Ohls RK. Erythropoietin-should it be used routinely? Practical NeonatalPharmacology Conference, Washington, DC

1995 Ohls RK. Erythropoietin to prevent and treat the anemia of prematurity. NewerPharmacologic Approaches in Neonatology, Annual Neonatal Symposium,Asheville, NC

1995 Ohls RK. Non-antibiotic treatment of infections. National Conference on PracticalNeonatal Pharmacology, Steamboat Springs, CO

1995 Ohls RK. Anemia of prematurity, erythropoietin, iron, and vitamin E. NationalConference on Practical Neonatal Pharmacology, Steamboat Springs, CO

1991 Ohls RK. Erythropoietin compared to transfusions in the treatment of anemia ofprematurity. American Academy of Pediatrics Annual Meeting, New Orleans, LA

1991 Ohls RK. Erythropoietin therapy for anemia of prematurity. Fellow ResearchPresentation, Mead Johnson Symposium in Perinatal and Developmental Medicine,Vail, CO

Local/RegionalOhls, Page 35

2015 Ohls RK. Drawing blood from a placenta (video presentation). AmazingNewborns Conference, University of New Mexico School of Medicine,Albuquerque, NM

2015 Ohls RK. Red Cell Mass in Neonates. Amazing Newborns Conference, Universityof New Mexico School of Medicine, Albuquerque, NM

2015 Ohls RK. Preschool Assessment of Preterm Infants Treated with Darbepoetin andErythropoietin. BRITE Investigator’s Meeting, University of New Mexico Schoolof Medicine, Albuquerque, NM

2015 Ohls RK. PENUT Investigator's Meeting2014 Ohls RK. Farmington Outreach Lecture: Fluids in Neonates. Farmington

Pediatrics, Farmington, NM2014 Ohls RK. PENUT Investigator's Meeting2013 Ohls RK. Collaborative Studies in Fetal Gene Expression. Southwestern Women’s

Options Conference, Albuquerque, NM2012 Ohls RK. Erythropoiesis stimulating agents for neonatal neuroprotection. Amazing

Newborns Conference, University of New Mexico School of Medicine,Albuquerque, NM

2011 Ohls RK. The Transition Period. Amazing Newborns Conference, University ofNew Mexico School of Medicine, Albuquerque, NM

2009 Ohls RK. Fluids, Electrolytes and Nutrition: the Goldilocks Principle. AmazingNewborns Conference, University of New Mexico School of Medicine,Albuquerque, NM

2000 Ohls RK. Transitioning from the Womb to the World. Another Look at theAmazing Newborn, Albuquerque, NM

1999 Ohls RK. Anemia in the First Month of Life. Wylder Lecture Series, University ofNew Mexico School of Medicine, Albuquerque, NM

1999 Ohls RK. Plethora and Pallor: Case Studies in the Newborn. Amazing NewbornsConference, Albuquerque, NM

1997 Ohls RK. Molecular and biological basis of erythropoietin regulation in anemia ofprematurity. General Clinical Research Center Site Visit, Albuquerque, NM

1994 Ohls RK. Erythropoietin in preterm infants. Pediatric Update, Department ofPediatrics, University of South Florida, Tampa, FL

1991 Ohls RK. Erythropoietin-alternative to blood transfusions. 14th Annual UtahPerinatal Association Conference, Salt Lake City, UT

1991 Ohls RK. Erythropoietin compared to transfusions for the anemia of prematurity.Intermountain Association of Neonatal Nurses Regional Meeting

Grand Rounds Presentations2019 Red Cell Transfusion Guidelines and Developmental Outcomes in Preterm Infants.

Neonatology Grand Rounds University of Utah, Salt Lake City, UT2019 Erythropoiesis Stimulating Agents as Neuroprotectants in Term and Preterm

Infants. University of Utah Robert D Christensen Annual Lecture on NeonatalHematology; Pediatric Grand Rounds, Salt Lake City, UT

2019 Erythropoiesis Stimulating Agents: Practical and Potential Uses in Neonates. Neonatology Grand Rounds University of Utah, Salt Lake City, UT

Ohls, Page 36

Jan 2011 Ohls RK. Transfusion Guidelines in Neonates. Department of Anesthesia GrandRounds, University of New Mexico School of Medicine, Albuquerque, NM

Oct 2004 Ohls RK. Darbepoietin: Potential Uses in Neonates. Grand Rounds, University ofNew Mexico School of Medicine, Albuquerque, NM

Feb 1991 Ohls RK. Erythropoietin administration for neonatal anemias. Department ofPediatrics Grand Rounds, University of Utah School of Medicine, Salt Lake City,UT

Ohls, Page 37